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Abstract 
     Expansion of visceral adipose tissue correlates with the metabolic syndrome 
and increased cardiovascular risk.  Hypertrophied visceral fat becomes inflamed, 
causing increased lipolysis, decreased triglyceride storage, and lipotoxicity in 
skeletal muscle and liver resulting in insulin resistance. Perivascular adipose 
tissue is a normal component of the adventitia of arteries in humans and animals.  
Whether or not perivascular adipose also becomes inflamed in obesity is an 
important question, as this may be an additional, direct mechanism by which 
obesity causes vascular inflammation and disease.  
     Thus, for the first part of my thesis, we asked the question: does perivascular 
adipose in mice become inflamed with high fat feeding? In contrast to visceral 
adipose, macrophage gene expression was not increased in perivascular 
adipose in response to high fat diet, and this correlated with reduced F480 
antigen positive cells as seen by immunohistochemistry and flow cytometry.  
Interestingly, perivascular adipose surrounding the thoracic aorta was similar to 
brown adipose tissue, a highly thermogenic fat depot, as shown by histology and 
DNA microarrays.  Moreover, inter-scapular brown adipose was also resistant to 
diet induced inflammation in comparison to visceral adipose.  These findings 
suggest that brown adipose in the perivascular niche may serve to protect the 
vasculature from diet induced inflammation, or from cold exposure, or both; 
whether or not brown perivascular adipose tissue exists in humans has yet to be 
determined.  
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     In the second part of my thesis, we evaluated the role of perivascular adipose 
tissue in the apolipoprotein E knockout mouse, which exhibits severe 
hyperlipidemia and atherosclerosis, but is resistant to diet induced obesity and 
glucose intolerance.  We tested the hypothesis that in this model of severe 
atherosclerosis, inflammation of perivascular adipose does occur.  However, we 
were surprised to find that macrophage specific gene expression, as determined 
by either microarray analysis or quantitative polymerase chain reaction, was not 
increased in either the perivascular or the visceral adipose of high fat diet fed 
apolipoprotein E knockout mice.  While the visceral adipose of wild type mice had 
extensive alterations in gene expression in response to high fat diet, in particular, 
enrichment of inflammatory gene expression and broad down regulation of 
peroxisome proliferator activated receptor gamma target genes, apolipoprotein E 
knockout visceral adipose did not.  Importantly, the apolipoprotein E knockout 
visceral adipose instead showed increased expression of genes encoding 
enzymes in fatty acid oxidation pathways.  High fat diet fed apolipoprotein E 
knockout visceral adipose was also characterized by smaller adipocyte size.  
     We conclude that, 1) inflammation in thoracic perivascular adipose does not 
occur in conjunction with diet induced obesity in normal animals nor with 
atherosclerosis in apolipoprotein E knockout mice, 2) thoracic perivascular 
adipose tissue is essentially identical to brown adipose tissue in mice, thus 
potentially protecting the vasculature from the cold, and 3) apolipoprotein E 
knockout mice remain lean on a high fat diet, despite hyperlipidemia and 
vii 
 
atherosclerosis, and the decreased adiposity correlates with decreased 
adipocyte size and adipose inflammation but increased oxidation of fatty acids. 
Consistent with previous work showing apolipoprotein E controls adipocyte 
uptake and deposition of triglyceride, its absence prevents adipocyte hypertrophy 
and resultant inflammation of visceral adipose tissue. Thus limiting adipocyte 
acquisition of fatty acids may be advantageous, provided that compensatory 
mechanisms to prevent sustained hyperlipidemia and peripheral organ 
lipotoxicity can be activated. 
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CHAPTER I: Introduction 
     It is estimated that 86.3% of adults in the United States will be obese or 
overweight in the year 2030[1].  At this rate, healthcare costs attributed to 
obesity/overweight will double every decade, to approximately 900 billion dollars 
in 2030; accounting for 15-20% of total US healthcare costs[1].  This expenditure 
is related to the cost of treatment of important co-morbidities such as diabetes 
mellitus, coronary artery disease, heart failure, and cancer.  The metabolic 
syndrome, which is mediated by insulin resistance, is thought to be the final 
common pathway by which obesity causes these disorders.   
   It is within this context that there has been a massive effort in the scientific 
community to understand the role of adipose tissue in normal and obese 
conditions.  There is no doubt that normal adipose tissue is extremely important 
to human physiology; the fact that patients with lipodystrophy suffer from the 
same risk of diabetes and cardiovascular disease as obese patients, highlights 
this physiologic importance.   Much of the basic science in the metabolism field 
has focused on ways in which adipocytes become dysfunctional in obese 
conditions.  This is with the recognition that making fat function better, by storing 
excess calories, may actually be beneficial.  The nuclear hormone receptor 
peroxisome proliferator activated receptor gamma (PPARγ) is the master 
regulator of adipocyte differentiation and function [2].  In clinical practice, efforts 
to promote normal function of adipose tissue using certain PPARγ agonists has 
recently been hampered by an increased risk of myocardial infarction [3].  This is 
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contrasted by a second school of thought which aims to promote the formation of 
brown adipose tissue (BAT), or fat that burns excess calories via fatty acid 
oxidation.  While efforts to activate brown fat with β3 adrenergic agonists have 
failed, efforts to promote BAT formation and activity remain a promising 
therapeutic strategy [4, 5].  By far the most important and effective therapy now 
and in the future will be the primary and secondary prevention of obesity by 
interventions on an individual, community, and global scale.  For those with 
established obesity bariatric surgery will become an increasingly important and 
effective option [6].  In the meantime, research efforts, such as that described 
herein, which aim to understand the role of physiology of adipose tissue in 
normal and obese conditions, will inform the future science and policy regarding 
this global health crisis. 
      
Obesity, Metabolic Syndrome and Cardiovascular Risk 
     Central obesity is associated with an increased risk of death and the 
development of atherosclerotic coronary artery disease, heart failure, and Type 2 
diabetes mellitus [7].  Although the exact mechanism by which this occurs is 
unknown, insulin resistance (IR), and the metabolic syndrome (MS) are thought 
to contribute [8, 9].  MS is a constellation of metabolic and underlying risk factors 
that promote the development of atherosclerotic cardiovascular disease (CVD) 
(Table 1.1).  Central obesity is a risk factor for developing this syndrome, as is 
3 
 
insulin resistance and associated conditions such as aging, physical inactivity, 
and hormonal imbalance [9].   
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TABLE 1.1. Clinical criteria for the diagnosis of Metabolic Syndrome 
 
 
 
 
 
Measure Categorical cut points 
Elevated waist circumference ≥102 cm (≥40 inches) in men 
≥88 cm (≥35 inches)  
in women 
Elevated triglycerides ≥150 mg/dL (1.7 mmol/L) 
or 
On drug treatment for elevated 
triglycerides‡ 
Reduced HDL-C ≤40 mg/dL (1.03 mmol/L) in men 
≤50 mg/dL (1.3 mmol/L) in women 
or 
On drug treatment for reduced 
HDL-C‡ 
Elevated blood pressure ≥130 mm Hg systolic blood pressure 
or 
≥85 mm Hg diastolic blood pressure 
or 
On antihypertensive drug treatment 
in a patient with a history of 
Hypertension 
Elevated fasting glucose ≥100 mg/dL 
or 
On drug treatment for elevated 
Glucose 
*Any 3 of 5 criteria 
 
‡Fibrates and nicotinic acid are the most commonly used drugs for elevated TG and 
reduced HDL-C. Patients taking one of these drugs are presumed to have high TG and 
low HDL 
 
Table adapted from Grundy et al.[9] 
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     Recent data has led to the recognition of two important limitations to the 
clinical criteria for the metabolic syndrome.  First, anthropometric measures of 
obesity such as body mass index (BMI) and waist circumference have limited 
sensitivity for visceral adiposity, and there are individuals with increased intra-
abdominal fat who do not meet clinical criteria for obesity; such patients should 
be considered  as “normal weight” obese [10].  Proxy measures of visceral 
adiposity such as the measurement of epicardial fat thickness with 2D 
echocardiography might be useful in these patients [11].  Second, insulin 
resistance is present at the tissue level long before clinically apparent 
manifestations such as elevated fasting blood glucose [8].  Selective defects in 
the phosphoinositide 3 kinase (PI3K) arm of insulin signaling, leading to impaired 
glycogen synthesis in skeletal muscle, is one of the first indications of insulin 
resistance in humans [8].  Therefore more sensitive measures of insulin 
resistance and MS are needed to detect patients who are at increased risk of 
CVD. 
     The predominant mechanism by which central adiposity leads to insulin 
resistance is thought to be related to “lipotoxicity”, a term first coined by Unger in 
1995[12].  In the setting of chronic caloric excess, visceral adipocytes 
hypertrophy, causing increased lipolysis and decreased storage of fatty acid as 
triglyceride (TG), resulting in increased plasma levels of non-esterfied fatty acids 
(NEFAS)[13].  Increased serum NEFAS accumulate as toxic lipid metabolites 
(e.g. fatty acyl CoA, diacylglycerols, ceramides) in liver and skeletal muscle, 
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causing insulin resistance [13].  This paradigm has come under scrutiny as of 
late, with evidence that lipolysis and subsequent increases in plasma NEFAs are 
actually reduced per unit of fat mass in obese humans [14, 15].  Additionally, 
mobilization of TG from post-prandial chylomicrons appears to be impaired in 
obese humans, owing to down regulation of mRNAs encoding lipoprotein lipase 
(LPL) and other genes responsible for uptake of fatty acid in adipose tissue[15].  
Nonetheless, there is no doubt that increased tissue levels of fatty acid 
metabolites causes IR in liver and skeletal muscle, as shown in humans using 
magnetic resonance spectroscopy and lipid infusions, and mice by tissue specific 
over expression of LPL [16-18].  The resultant IR in skeletal muscle and liver is a 
harbinger of the clinically apparent components of MS (Table 1.1).   
     Impaired insulin stimulated glucose uptake in skeletal muscle contributes to 
hyperglycemia, leading to increased insulin secretion and hyperinsulinemia [8].   
Hepatic “selective insulin resistance” in the PI3K pathway accounts for the 
hypertriglyceridemia which accompanies MS and Type 2 Diabetes.  The failure of 
insulin to stimulate protein kinase B (PKB/Akt) phosphorylation results in 
constitutive Forkhead box protein O1 (Foxo1) activity in the nucleus, leading to 
increased transcription of genes responsible for hepatic gluconeogenesis 
(e.g.Pepck,G6PC) and increased hepatic glucose output [19, 20](Figure 1.1).  In 
contrast, insulin continues to stimulate sterol regulatory element binding protein 
1c (Srebp1-c), which transcribes enzymes responsible for fatty acid synthesis, 
leading to increased hepatic very low density lipoprotein (VLDL) output and 
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hypertriglyceridemia [19, 20].  In addition, hyperinsulinemia causes stimulation of 
mitogen activated protein kinase pathways in peripheral tissues, resulting in 
increased vascular smooth muscle cell proliferation, collagen formation, and 
excessive production of growth factors and inflammatory cytokines [8].  The 
adverse effects of hyperinsulinemia caused by exogenous insulin treatment are 
yet unknown, but apparent as an average 8.6 kg weight gain in type 2 diabetic 
patients starting insulin despite an improvement in HbA1c% [8].   
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TYPE 2 DM: SELECTIVE INSULIN RESISTANCE
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FIGURE 1.1  Selective insulin resistance in the liver contributes to the 
hyperglycemia and hypertriglyceridemia of Type II diabetes mellitus.  In 
normal conditions (top), the pancreas secretes insulin in response to glucose.  
Insulin triggers inhibitory phosphorylation of FoxO1, which then fails to activate 
transcription of mRNAs encoding gluconeogenic enzymes.  Srebp-1c is 
stimulated normally to activate transcription of fatty acid synthesis genes which 
synthesize TG to fuel peripheral tissues.  In obese conditions (bottom), 
hyperglycemia stimulates hyperinsulinemia.  The liver is resistant to insulin in the 
Akt pathway and cannot stimulate inhibitory phosphorylation of FoxO1; 
transcription of gluconeogenic enzymes continues and hepatic glucose output 
increases.  “Selective insulin resistance” allows for hyperactivation of the Srebp-
1c pathway, which is not insulin resistant, increasing hepatic VLDL output.  
Increased blood TG contributes to lipotoxicity of skeletal muscle, liver and other 
tissues.  X=insulin resistance, SKM=skeletal muscle, TG=triglyceride.  Adapted 
from Brown et al. 2008[19]. 
 
9 
 
Role of Inflammation in Human Adipose Tissue 
     The production of inflammatory cytokines by human adipose tissue was first 
reported by Hotamisligil et al. in 1995, when they demonstrated greater tumor 
necrosis factor alpha (TNFα) mRNA and protein in the subcutaneous adipose 
tissue (SAT) of obese compared to lean pre-menopausal women [21].  Adipose 
tissue TNFα levels correlated with hyperinsulinemia, and it was hypothesized that 
TNFα contributed to IR in fat in an autocrine or paracrine fashion, as plasma 
levels were undetectable.  Weight loss led to reductions in TNFα production by 
adipose tissue in some of the subjects [21].  Subsequently, Weisberg et al. found 
increased expression of macrophage specific genes in the SAT of obese humans 
[22].  Using immunohistochemistry for the mature macrophage marker F480 
antigen (F480), the authors showed that the percentage of tissue macrophages 
correlated positively with adipocyte cell size and BMI.  In lean humans, 
macrophages were estimated to number 10% of the total cells in adipose tissue, 
whereas almost 40% of the cells in adipose tissue of obese subjects were F4/80+ 
[22].  The majority of these F480+ cells were present in multinucleate syntitia or 
“crown like structures”(CLS), which surround dead or dying adipocytes [23].  
Hence, adipocyte cell death was thought to be one of the triggers for 
macrophage recruitment to adipose tissue, where they function to scavenge toxic 
free fatty acids and cellular debris [22].   
     Multiple subsequent studies have shown increased macrophage infiltration in 
SAT and visceral adipose tissue (VAT) of obese humans [23-26].  The 
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percentage of macrophage accumulation in VAT is greater than SAT and 
correlates directly with the degree of abdominal adiposity (r=0.535, p<0.0001), 
cell size, individual components of MS, and hepatic steatosis [26, 27].  Once 
present, macrophages and other immune cells secrete pro-inflammatory 
cytokines such as TNFα, interleukin 1 beta (IL1β), and interleukin 6 (IL6) and 
establish a chronic immune response.  Cytokines exaggerate the dysregulated 
metabolism of local adipocytes, increasing lipolysis, decreasing TG esterfication, 
and reducing production of beneficial adipokines such as adiponectin (ADPN); 
these effects are mediated in part by TNFα which down regulates adipocyte 
PPARγ mRNA and protein [13].  Thus inflammation in human adipose tissue, 
which may initially serve as a protective effect, becomes exaggerated and 
chronic, resulting in adipocyte dysfunction, deleterious effects on the liver, and 
systemic inflammation manifest as increases in serum acute phase reactants 
such as C-reactive protein (CRP), orosomucoid, and serum amyloid A [13, 28].  
Weight loss induced by gastric bypass has been shown to decrease the number 
of macrophages in SAT, decrease the expression of inflammatory chemokines, 
and alter the activation state of remaining macrophages, as shown by increased 
expression of the anti-inflammatory cytokine interleukin 10 (IL10) [28].  Although 
this unrestrained and chronic inflammatory response in human VAT is 
deleterious to whole body metabolism, these studies underestimate the 
complexity of adipose physiology.  
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Inflammation in mouse models of diet induced obesity 
     Studies in mouse models of diet induced obesity (DIO) have been crucial in 
defining this complex relationship between innate immunity and metabolism.  
Two reports in 2003 highlighted the establishment of a chronic inflammatory 
condition in the VAT of dietary and genetic mouse models of obesity [22, 29].  In 
the context of human data, three primary questions remain: 1) is inflammation in 
VAT a direct cause of whole body insulin resistance? 2) why is visceral fat 
disproportionately affected by inflammation? and 3) what is primary stimulus for 
inflammation? 
     In regards to the first question, Strissel et al. showed that within 6-8 weeks of 
starting a high fat diet (HFD), there is a threefold increase in the stromal vascular 
cell number in adipose tissue [30].  mRNAs for F480, Cd11 antigen like family 
member C (Cd11c/Itgax), Cd68 antigen (Cd68), and Tnfα become significantly 
increased when compared to normal diet control mice at this time point 
[30](Figure 1.2).  This is coincident with increased adipocyte cell size and the 
onset of adipocyte cell death (16% of adipocytes).  Importantly, fasting plasma 
glucose, homeostasis model of assessment-insulin resistance (HOMA-IR), and 
the area under the curve for the insulin tolerance test all were significantly 
elevated at this time, suggesting that inflammation in VAT contributes to whole 
body IR [30, 31].  With the large increase in adipocyte death in VAT, and an 
apparent reduction in differentiation of new cells, there is a 40% net loss in VAT 
mass [30].  By 16 weeks of HFD there is increased fibrosis and collagen 
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formation in adipose tissue, decreases in Tnfα and Cd11c mRNA, and increases 
in Il10.  Interestingly, by 20 weeks of HFD, insulin resistance is actually improved 
compared to 16 weeks, albeit not to baseline levels [30].  This signifies a switch 
back to an “alternatively activated” M2 phenotype, which is reminiscent of 
adipose tissue macrophages from lean mice not exposed to HFD [32].   
     In contrast to VAT, there is a sustained 10 fold increase in the mass of SAT 
during HFD [30].  This is due to both increased adipocyte size and a doubling of 
adipocyte number.  However, the mean size of subcutaneous adipocytes 
remains less than half of that seen in VAT and the rate of cell death in SAT never 
exceeds 3%, whereas in VAT it reaches 80% after 16 weeks of HFD [30].   
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FIGURE 1.2  Time course of pathophysiologic change in VAT and 
metabolism in the DIO model.  The number of inflammatory cells in the visceral 
fat gradually increases during high fat feeding.  After 6-8 weeks of HFD mRNAs 
encoding F480, Cd11c, and Tnfα become significantly enriched in VAT.  This is 
coincident with increasing adipocyte size and increases in adipocyte cell death.  
That inflammation in VAT causes whole body IR is suggested by the onset of IR 
(white background) at 8 weeks, when the inflammatory cell number and 
representative mRNAs become enriched.  The peak of adipocyte cell death 
(80%) at 16 weeks, signals a transition of macrophages to M2 polarization, with 
decreased Tnfα mRNA and increased Il10 mRNA.  At 20 weeks, measures of 
insulin resistance are actually improved compared to 16 weeks, but not back to 
baseline.  Note that the net loss of visceral fat mass is accommodated by high 
rates of cell death, and a greater number of smaller adipocytes at 20 weeks.  
Data from Strissel et al.[30] 
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     In summary these studies have been crucial to our understanding of 
inflammation in adipose tissue by confirming that macrophage infiltration 
correlates with increased cell size, cell size and rates of cell death are 
significantly greater in VAT, and these events correlate with the onset of insulin 
resistance.  An important question that remains is: what is the initial stimulus for 
macrophage infiltration in obesity?  We will focus on three specific possibilities: 
adipocyte death, free fatty acids, and chemokines. 
Factors Which Contribute to Immune Cell Recruitment 
Adipocyte Death 
     Macrophage infiltration in humans is directly and positively correlated with 
BMI and adipocyte cell size [22, 23, 25].  Two papers have shown definitively that 
bone marrow derived monocytes home to adipose tissue where they are 
attracted to dying adipocytes [23, 30].  Dying adipocytes are surrounded by a ring 
of activated macrophages which form a “crown like structure” containing 
multinucleated giant cells (MGC)(Figure 1.3).  MGCs are a feature of chronic 
inflammation due to persistent mycobacterial infections, non-infectious 
granulomatous diseases (e.g. sarcoidosis, rheumatoid arthritis) or the presence 
of non-phagocytosable foreign bodies [33].  Transmission electron microscopy 
showed that hypertrophied adipocytes develop features of necrotic cell death, 
including ruptured plasma membranes, dilated endoplasmic reticuli, and cellular 
debris in the extracellular space [23].  Furthermore, expression of lipid droplet 
proteins such as adipophilin (Adrp) and perilipin (Plin1) is reduced.   That 
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macrophages engulf the released free fatty acids and cholesterol is suggested by 
the fact that they develop lipid droplets and induce expression of the same lipid 
droplet proteins (e.g. Adrp, Plin1) [23].  The authors then showed that adipocyte 
hypertrophy was crucial to the development of cell death, using hormone 
sensitive lipase (Hsl) null mice.  Mice with deletion of Hsl cannot hydrolyze stored 
triglyceride in response to metabolic cues, and therefore develop large 
adipocytes; the cell size of Hsl-/- adipocytes was three fold greater than wild type 
on normal diet.  After 12 weeks, there was a 15 fold increase in CLS formation in 
Hsl-/- compared to controls (29 CLS per 100 adipocytes vs. 2 CLS per 100 
adipocytes)[23].  Hence, it appears that adipocyte hypertrophy is a source of 
cellular stress which triggers necrotic death.  Potential sources of cellular stress 
in larger sized adipocytes include ER stress, hypoxia, increased TNFα 
expression, altered cholesterol concentrations, reactive oxygen species, or 
increased local free fatty acids [34].  In light of recent evidence, free fatty acids 
are a particularly attractive candidate as entities which may promote the initial 
inflammatory response. 
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FIGURE 1.3. Macrophage infiltration of VAT with HFD and the β3 agonist 
CL316,243.  Shown at left are F480+ macrophages after 13 weeks of HFD in the 
visceral fat of mice.  On the right, hematoxylin & eosin staining of visceral fat 16 
hours after treatment with the β3 agonist CL316,243.  At left, a multinucleate 
giant cell can be seen (arrow) within a crown like structure.  Macrophages in this 
case are likely attracted to visceral fat to phagocytose the remnants of dying 
adipocytes (surrounded by macrophages).  On the right, although a macrophage 
specific stain was not used, note the multiple single nuclei cells between 
adipocytes, without crown like structure formation.  (Tim Fitzgibbons, 
unpublished data) 
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Lipolysis 
     Adipocytes store fatty acids in the form of triglyceride, which can be 
hydrolyzed to provide oxidative fuels to peripheral tissues at times of energy 
deprivation such as fasting or exercise.  Adipocytes have two modes of lipolysis, 
a basal continual low level, and a hormone stimulated or “demand” lipolysis [34].  
The rate of basal lipolysis is directly proportional to cell surface area (4πr2), and 
therefore increases dramatically in larger adipocytes.  Given this, and the fact 
that macrophage accumulation positively correlates with cell size and BMI, 
Kosteli et al. asked the question “is adipocyte lipolysis responsible for 
macrophage recruitment to adipose tissue?”[34].  Lipolysis should be greatest in 
large adipocytes (high basal lipolysis) which are subject to demand lipolysis 
(fasting or weight loss).  To test this hypothesis, they performed a series of 
elegant experiments using both caloric restriction (CR) and fasting of obese 
mice.  After 3 days of CR (70% ad libitum fed), or 24 hours of fasting, there was a 
dramatic increase over baseline in the percentage of macrophages in VAT 
(26.3% vs. 38.6% of total cells for CR, 22.9% vs. 37.9% for fasting) and in 
expression of the macrophage specific genes F480 and colony stimulating factor 
receptor 1 (Csfr1) [34](Table 1.2).  This was accompanied by increased serum 
free fatty acid (FFA) levels, and increased lipolysis in explants of adipose tissue 
from the same mice.  Stimulation of lipolysis with a β3 adrenergic agonist 
(CL316,243) also induced potent macrophage accumulation within 24 hours.  To 
confirm that macrophages were responding to increased lipolysis of adipocytes, 
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the authors then performed fasting in mice deficient for the major TG lipase, 
desnutrin or (Atgl).  Atgl-/- knockout mice have very low levels of basal lipolysis 
and are unable to stimulate demand lipolysis in response to fasting.  When 
compared to control mice, ad libitum fed Atgl-/- knockout mice had decreased 
numbers of macrophages in adipose tissue, and there was no increase seen 
after 24 hours of fasting [34].       
     Despite the dramatic increases in macrophage accumulation after 3 days of 
CR, 24 hours of fasting, and injection of the β3 agonist, there was no increase in 
expression of inflammatory genes such as Cd11c or Tnfα, and mice remained 
insulin sensitive in all conditions [34].  This is in stark contrast to the increased 
expression of inflammatory genes (e.g. Tnfα, IL6, IL1b) which accompanies 
macrophage infiltration in obese conditions [22, 29, 30].  The authors proposed 
that short term alterations in lipid flux, due to fasting or CR, result in a transient 
increase in macrophage infiltration, which gradually resolves without promoting 
inflammation and peripheral insulin resistance.  In the setting of chronic high fat 
feeding, accumulated macrophages become inflammatory, expressing Cd11c 
and cytokines, and causing peripheral insulin resistance.  This situation is 
somewhat analogous to foam cell formation seen in atherosclerotic plaques.  
Once established, if the primary insult (e.g. hyperlipidemia) is resolved, by 
treatment with statins for example, macrophages may exit and plaque may 
regress.  However, with continued chronic exposure to high cholesterol or other 
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risk factors, macrophages themselves are activated, unable to egress, secrete 
inflammatory cytokines and even undergo apoptosis [35].   
     In summary, FFAs released from adipocytes may serve as the initial stimulus 
for macrophage accumulation.  FFAs may stimulate Toll-like receptor 4 (Tlr4) on 
adipocytes, or endothelium, to up regulate adhesion molecules and chemokines 
which attract monocytes from the bloodstream [36].  However, there are several 
key distinctions to be made between the inflammation in adipose tissue seen in 
obesity and fasting (Table 1.2).  Macrophages in diet induced obesity form CLS, 
express macrophage markers such as F480, CD11 like antigen family member B 
(Cd11b/Itgam) and Cd11c/Itgax, and transcribe genes encoding inflammatory 
cytokines (Tnfα, Mcp-1, Il6).  In mice, this inflammation associated with a 
reduction in adipocyte cell number and an increase in peripheral IR.  In fasting 
conditions, although there are increased macrophages in adipose tissue, they 
tend not to form CLS, they express only F480 and Cd11b, and inflammatory 
cytokine production is not increased (Table 1.2).  Finally, although there is a 
reduction in cell size, there is not a reduction in cell number nor is there an 
increase in peripheral insulin resistance during fasting or CR. 
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TABLE 1.2. Differences between adipose inflammation in mice in HFD 
induced obesity and fasting/CR 
 Obesity Fasting/CR 
Macrophage number and 
morphology 
-Up to 50% of adipose 
tissue cells 
-CLS and MNGC 
-Up to 38% of adipose 
tissue cells vs. 26% in 
obese control mice 
-non CLS macrophage 
accumulation 
Macrophage markers 
 
F4/80, Cd11b, Cd11c F4/80, Cd11b 
Inflammatory gene 
expression 
 
↑↑Tnfα, Il6, iNOS, Mcp-1 Not increased compared to 
control mice 
Adipocyte cell death 
 
Present Absent 
Adipocyte cell size 
 
Increased Decreased 
Metabolism 
 
Insulin resistant Insulin sensitive 
Serum FFA Increased 
0.6 vs. 0.4 mmol/L in chow 
fed 
Increased 
0.8 vs. 0.6 mmol/L in 
obese, fed 
CLS=crown like structures, MNGC=Multinucleate giant cells 
Data from references [22, 30, 34] 
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Chemokines 
     There are likely multiple redundant mechanisms which promote greater 
macrophage infiltration into VAT than SAT, including cell death, hypoxia, 
lipolysis, and chemotactic regulation [37].  The latter mechanism appears 
particularly important.  Studies in mice have shown that diet induced obesity 
(DIO) stimulates a robust increase in transcription of chemokine genes such as 
macrophage chemoattractant protein 1 (Mcp-1), Regulated upon Activation 
Normal T-cell Expressed and Secreted (RANTES/Ccl5), and macrophage 
inhibitory protein 1 alpha (Mip1α/Ccl3) in VAT [22, 29].  In obese humans, 
expression of chemokine genes such as MCP-1, plasminogen activator, 
urokinase receptor (PLAUR), and colony stimulating factor 3 (CSF-3) is 
increased and associated with macrophage infiltration and CLS formation in SAT 
[28].  3 months after gastric bypass surgery, during which time an average of 20 
kg fat mass was lost, there was a dramatic reduction in macrophage number and 
virtual disappearance of CLS formation [28].  This was associated with 
decreased transcription of MCP-1 and CSF-3 mRNAs (25 and 10 fold 
respectively).  Macrophages, rather than adipocytes, were mostly responsible for 
expression of these factors [28].   
     A second human study matched gastric bypass patients for BMI, 
dichotomized them into IS (HOMA2-IR < 2.3) and IR (HOMA2-IR ≥ 2.3) groups, 
and then performed microarray analyses on omental fat [25].  Interestingly, the 
only two Gene Ontology (GO) terms significantly different between groups were 
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“chemokine activity” and “chemokine receptor binding”.   Among the 37 genes 
differentially expressed were the chemokines MCP-1/CCL2, MIP1α/CCL3, 
macrophage inhibitory protein 1 beta (MIP1β/CCL4), chemokine (C-C motif) 
ligand 18 (CCL18), and interleukin 8 (IL8/CXCL8) [25].  MCP-1 is perhaps the 
most well studied of these genes in mouse models [38-40]. 
       Kanda et al. published a paper that strongly suggested the adipocyte was a 
major source of Mcp-1 [39].  Mcp-1 mRNA expression was induced in 3T3LI 
adipocytes cells following glucose deprivation, and greatly increased in both the 
stromal vascular fraction and adipocyte fraction of HFD fed mice [39].  Adipocyte 
specific over-expression of Mcp-1 and whole body Mcp-1 knockout, resulted in 
increased and decreased macrophage infiltration into VAT respectively.  
Chemokine (C-C motif) receptor 2 (Ccr2) knockout mice also have reduced 
macrophage infiltration into VAT, supporting the notion that adipocyte secreted 
Mcp-1 is a ligand for Ccr2 on macrophages [40].    However, there is some 
controversy in the literature regarding Mcp-1, as two subsequent studies in whole 
body Mcp-1-/- mice demonstrated no differences between WT or KO mice in 
macrophage infiltration of VAT or whole body insulin sensitivity after HFD[38, 41].  
It is possible that the macrophage Mcp-1 receptor (Ccr2) recognizes multiple 
chemokines, hence there is some redundancy in these molecules and whole 
body deficiency of Mcp-1 may not have an effect in some circumstances. 
     Adipose tissue is a dynamic organ which contains many cell types, including 
adipocytes, pre-adipocytes, endothelial cells, stems cells and immune cells [42].  
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In fact, it is estimated that over 90% of adipokine release, except for that of 
adiponectin and leptin, is due to non-fat cells, either the matrix or the stromal 
vascular cell (SVC) fraction [42].  An important question which has yet to be 
answered definitively is which is the exact cell in adipose tissue that secretes 
Mcp-1 in response to high fat feeding?  
     A recent study by Ohman et al. was very informative in this regard [43].  The 
authors have previously shown that transplantation of VAT to apolipoprotein E 
knockout (Apoe-/-) mice increases inflammation and atherosclerosis in these mice 
in comparison to non transplanted controls or those transplanted with SAT[43].  
Using this model, the authors attempted to determine what cell type is the 
relevant source of Mcp-1.  When VAT was transplanted to Apoe-/- mice there was 
increased atherosclerosis and plasma Mcp-1 compared to non transplanted 
controls (78.7 vs. 31.4 pg/mL).  In contrast, when VAT was transplanted into 
Apoe-/- Mcp-1-/- double knock-out mice, there was no increase in atherosclerosis 
and plasma Mcp-1 was barely detectable.  Therefore, the source of circulating 
Mcp-1 is not the donor adipocytes [43].   Using bone marrow transplantation, the 
authors went on to show that the endothelium is the predominant source of 
circulating Mcp-1 in acute and chronic inflammation, although leukocytes do 
provide some local Mcp-1 in VAT [43].        
     In summary, it appears Mcp-1 is an important factor which stimulates the 
infiltration of macrophages into VAT.  It is likely that increased FFA release, 
reactive oxygen species, or ER stress of visceral adipocytes cause activation of 
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the resident endothelium or tissue macrophages, leading to increased Mcp-1 
expression and macrophage infiltration.  Preliminary data from our laboratory 
suggests that the endothelium regulates monocyte infiltration into visceral fat, by 
altering expression of adhesion molecules in response to metabolic cues (Rachel 
Roth, unpublished data).   
Pathophysiology of Atherosclerosis 
The “Response to Retention” Hypothesis 
     The past two decades have led to an exponential increase in our 
understanding of the pathophysiology of atherosclerosis, much of which became 
possible with two simultaneous reports of the creation of the first transgenic 
mouse model of atherosclerosis, the Apoe-/- mouse [44, 45].  Mice are inherently 
resistant to atherosclerosis, partially because they have low serum cholesterol on 
a chow diet (60-80 mg/dL), mostly in the form of high density lipoprotein (HDL) 
[46].  The Apoe-/- mouse has extremely high plasma total cholesterol and TG due 
to inability to uptake chylomicron remnants and VLDL.  Despite the development 
of severe atherosclerosis, this model is not prone to plaque rupture, which is the 
process which ultimately leads to the morbidity and mortality of human subjects.  
Nonetheless, the Apoe-/- and low density lipoprotein receptor (LDLr-/-) mouse 
have contributed greatly to our understanding of the pathophysiology of 
atherosclerosis, which has gradually evolved to the current paradigm in which 
atherosclerosis is an inflammatory disease of medium and large arteries which is 
initiated by the sub-endothelial retention of LDL.   
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    Cholesterol is transported in the blood predominantly by LDL which contains 
esterfied cholesterol, triglyceride, phospholipids, and apolipoprotein B100.  
apoB100 binds to proteoglycans in the arterial intima, leading to sub-endothelial 
trapping of lipoproteins, and exposing the lipids to oxidative modification by 
myeloperoxidase, lipoxygenase, and reactive oxygen species [47](Figure 1.4).  
Oxidatively modified lipids such as lysophosphatidylcholine  activate endothelial 
cells and macrophages, resulting in increased expression of adhesion molecules 
E-selectin (SELE) and vascular cell adhesion molecule 1(VCAM-1), chemokines 
(Mcp-1/CCL2, RANTES/CCL5, chemokine (C-X-C) motif ligand 10 (CXCL10)) 
and growth factors (macrophage-colony stimulating factor (M-CSF))[47].  
Circulating blood monocytes then adhere to the activated endothelium, 
diapedese, and enter the arterial intima where they differentiate into 
macrophages.    
     Macrophages are the predominant immune cell type of plaques, but T cells 
are also present (4:1 or even 10:1 ratio)[47].  Macrophages express scavenger 
receptors such as macrophage scavenger receptor 1 (SRA), macrophage 
receptor with collagenous structure (MARCO), CD36 antigen (CD36), scavenger 
receptor class B, member 1 (SR-B1), and lectin type oxidized LDL receptor 1 
(LOX-1) which uptake modified lipids and cellular debris resulting in the 
development of “foam cells”.  Macrophages initially serve a protective function, 
scavenging oxidatively modified lipid and toxic free cholesterol in the process of 
efferocytosis [35].  Furthermore, because this cholesterol remains intracellular 
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and soluble, instead of extracellular in the form of crystals, it can be exported via 
ABC type transporters to HDL for reverse cholesterol transport to the liver [35].  
However, factors which cause increased macrophage cellular stress, such as 
excess cholesterol, insulin resistance, or ER stress, lead to macrophage 
apoptosis and the release of intracellular cholesterol [35].  This process 
contributes to the “necrotic core” of atherosclerotic plaques, which are prone to 
rupture and the development of acute coronary syndromes.  In addition, 
continued exposure of macrophages to modified LDL results in stimulation of 
innate immunity, prompting cytokine release, and the recruitment of other 
immune cells to the lesion, which in turn, prompt the transition to  adaptive 
immunity and chronic inflammation [48].  Two specific stimuli for macrophage 
innate immunity are oxidized LDL derived epitopes via Toll Like Receptors (TLR) 
and cholesterol crystals via the inflammasome protein receptor NLR family , pyrin 
domain containing 3 (NLRP3)[49-51].  Finally, continued hypercholesterolemia 
results in loss of protective regulatory T cells from the vessel wall, whereas 
cholesterol lowering preserves their number and function [48]. 
     Therefore, just as in adipose tissue, the macrophage appears to orchestrate 
an immune response in the atherosclerotic plaque which may initially be 
protective.  However, in the setting of chronic metabolic stress, the macrophage 
becomes dysfunctional and even apoptotic, leading to increased inflammation, 
matrix metalloproteinase release, and plaque rupture. 
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 FIGURE 1.4.  The “Response to Retention Model” of Atherosclerosis.  The 
sub-endothelial retention of apoB containing lipoproteins triggers activation of 
adhesion molecule expression in endothelium.  Monocytes are then attracted and 
adhere, diapedese, and differentiate into macrophages.  Macrophages of 
established atherosclerotic plaque scavenge oxidatively modified lipid and 
transport cholesterol out of the vessel.  Chronic cell stress (e.g. continue 
hyperlipidemia, ER stress, insulin resistance) cause macrophage apoptosis, 
leading to the necrotic core and increased risk for plaque rupture.  Figure 
adapted from Moore et al.[35] 
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Perivascular Fat and the “Yudkin Hypothesis” 
     The “response to retention” hypothesis holds that atherosclerosis develops 
from the arterial intima to the media, or from “inside to outside”(Figure 1.4).  
However, recently there has been interest in an alternative hypothesis, which 
posits that atherosclerosis and other vascular diseases are initiated or promoted 
by factors within the adventitia, with disease proceeding from “outside to inside” 
the arterial wall (Figure 1.5)[52-54].  Although this concept has long standing 
experimental support, there are three principal findings which have led to the 
promotion and sustained investigation of this possibility [55-58].   
     First, recent studies have shown increased adventitial macrophages 
associated with expansion of the  vasa vasorum in early atherosclerotic lesions 
prior to plaque neovascularization [52].  Second, following balloon angioplasty of 
porcine coronary arteries, there is a profound inflammation of the adventitia, 
which is followed by neointimal hyperplasia [57].  This also suggests that factors 
within the adventitia regulate intimal disease.  Finally, there are local deposits of 
fat surrounding arterioles which supply skeletal muscle.  Insulin stimulates robust 
capillary recruitment in skeletal muscle by stimulating nitric oxide mediated 
vasodilation [59].  However, in obese conditions, nitric oxide synthesis is 
impaired, resulting in unopposed vasoconstriction, mediated by Endothelin-1.  
This impairment in nitric oxide production is thought to be due to release of TNFα 
by local fat which acts in a vasocrine fashion to inhibit insulin signaling in the 
adjacent endothelium [59].  As with visceral fat, adipocytes within these 
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regulatory perivascular fat depots hypertrophy in obese conditions, and 
depending upon the anatomical context and metabolic milieu, are prone to 
inflammation.  Inflammation in perivascular adipose tissue (PVAT) may directly 
impact vascular disease of the underlying artery, perhaps contributing to 
atherosclerosis, peripheral vascular disease, hypertension, or arteriosclerosis.   
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FIGURE 1.5. Proposed role of PVAT in vascular health and disease.  In lean 
conditions (top), PVAT functions normally, signaling through PPARγ to secrete 
beneficial cytokines such as adiponectin (ADPN) in a paracrine manner.   ADPN 
inhibits VSMC hyperplasia, vasodilates smooth muscle, and prevents 
inflammation.  In obese conditions (bottom), PVAT hypertrophies, macrophages 
infiltrate, and inflammatory cytokines such as TNFα are secreted.  TNFα down 
regulates PPARγ through transcriptional and post-transcriptional mechanisms, 
leading to decreased secretion of adiponectin and other beneficial factors by 
PVAT.  Potential consequences of decreased adipokines are increased VSMC 
proliferation, vasoconstriction, and vascular inflammation. 
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Evidence for a Role of Perivascular Fat in Cardiovascular Disease 
Human Studies 
    In reviewing the literature on the role of perivascular fat in vascular disease, it 
becomes evident that the findings depend upon several variables in particular:  1) 
the species and the strain of animal studied, 2) whether or not the subject is lean 
or obese, and 3) the anatomic context of the fat and vessel studied.   It should be 
emphasized that PVAT is a normal component of the arterial adventitia in 
mammals.  It surrounds the coronary arteries (epicardial fat), aorta (periaortic 
fat), and microvasculature of the brain, mesentery, skeletal muscle, and kidney 
[59].  PVAT should not be considered an ectopic fat depot per se, but a normal 
fat depot that is subject to the plasticity of other fat depots observed in lean and 
obese conditions. 
     In humans, the first evidence that PVAT was associated with vascular disease 
came from a report by Mazurek et al. in 2003 [60].  Paired samples of epicardial 
and subcutaneous adipose tissue were obtained from 42 patients with coronary 
artery disease (CAD) undergoing coronary artery bypass graft surgery.  mRNA 
and protein expression of inflammatory genes was compared in epicardial 
adipose tissue (EAT) versus SAT in the same patients [60].  mRNA expression of 
IL-1β, IL-6, MCP-1, and TNFα was significantly increased in the EAT versus the 
SAT of all patients.  Protein release of these same factors by EAT explants in 
conditioned media was also significantly increased, ranging from 7.0 fold for IL6 
(3.4-70.8, p<0.001) to 118.6 (12.6-7416, p<0.001) for TNFα [60].  
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Immunohistochemistry showed dense infiltrates of inflammatory cells in EAT 
including macrophages, T cells, and mast cells, whereas there were no such 
infiltrates in SAT.  The inflammatory features of EAT were present despite the 
fact that 50% of patients were taking statins and 93% were taking aspirin [60].  
Furthermore, the release of cytokines by EAT did not correlate with plasma levels 
of cytokines, suggesting that they were in fact paracrine mediators which could 
not be impacted by systemic anti-inflammatory medications.   
     This study raised several interesting questions.  Was the inflammation present 
before the development of CAD, was it a result of the CAD, or simply an 
epiphenomenon?  Did the inflammation closely correlate with local 
atherosclerotic lesions?  Was there inflammation in VAT of the same patients?  
Despite these questions, this study remains the most significant and interesting 
in the field to date. 
     A second paper by Henrichot et al. studied PVAT surrounding the aortas of 
humans with abdominal aortic aneurysms [61].  They found that PVAT 
surrounding the abdominal aorta secreted MCP-1 and IL-8, in concentrations 
similar to SAT from the same patients.  In atherosclerotic aortas, local PVAT 
contained CD68+ and CD3+ cells [61].  These cells were more numerous in the 
PVAT directly adjacent to the aorta than in the peripheral PVAT; however, they 
were still greater in PVAT than in SAT or in PVAT from non-diseased arteries.  
Conditioned media from PVAT was chemotactic for granulocytes, monocytes, 
and T cells in transwell assays, although not greater than SAT [61].  The two 
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major findings of this study were that 1) PVAT surrounding the atherosclerotic 
aorta contains inflammatory cells and 2) PVAT expresses MCP-1 and IL8 which 
are functional  in transwell assays.  The authors speculated that PVAT may be 
particularly relevant in obesity associated vascular disease [61].   
     Multiple subsequent human studies have demonstrated that PVAT around 
coronary arteries (i.e. EAT), expresses increased mRNAs encoding inflammatory 
genes [60, 62-64].  More recently, others have demonstrated that PVAT might 
have a beneficial effect in lean humans [62, 65].  Karasterigiou et al.  studied 
EAT in four groups of patients: normal weight patients with and without CAD 
(BMI  ≤27 kg/m2) or obese patients with or without CAD (BMI ≥ 27 kg/m2) [62].  
Even in lean patients without CAD, EAT was found to secrete 13 cytokines into 
conditioned media.  Of these 13, CCL5/RANTES was the only cytokine 
significantly independently associated with the presence of CAD [62].  
Interestingly, adiponectin was found to be independently associated with both 
BMI and the presence of CAD.  That is, in comparison to controls, adiponectin 
release from EAT was decreased in obese patients and in lean patients with 
CAD [62].  Serum adiponectin concentrations were not decreased in the lean 
CAD group.  That CAD is associated with a reduction in adiponectin secretion by 
EAT has been confirmed by other groups [66-68].  Adiponectin has anti-
inflammatory properties and has been shown to reduce the adhesion of 
monocytes to human coronary endothelial cells in vitro [62].     
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     The beneficial properties of PVAT derived adiponectin were recently extended 
to a role in the direct stimulation of nitric oxide production in vascular 
endothelium [65].  PVAT surrounding small arteries in subcutaneous fat from 
healthy lean controls promoted endothelium dependent vasodilation of the 
underlying artery.  This vasodilatory effect was lost with removal of the PVAT, 
and also with incubation with an Adiponectin type 1 receptor antibody or a nitric 
oxide synthase inhibitor (L-NAME)[65].  This vasodilatory effect of PVAT was 
absent in obese patients, in whom the cell size of perivascular adipocytes was 
greater, and associated with immunohistochemical evidence of inflammation 
(increased TNFR1 staining). This was the first study in humans to confirm the 
initial hypotheses of Yudkin, that PVAT from healthy subjects exerts a 
vasoprotective influence which is abrogated in obese conditions [59].   
     In summary, data from humans has shown that PVAT, much like VAT, has 
evidence of inflammation in obesity and in cardiovascular diseases such as CAD 
or peripheral vascular disease.  It has not been established whether or not 
inflammation in PVAT is causative or merely with associated disease.  
Furthermore, it is not known whether there is inflammation in the VAT of the 
same patients, which would indicate whether or not EAT is an autonomous fat 
depot which may independently promote disease, or is merely a marker for 
visceral adiposity.  Clinical imaging studies suggest that the latter is the case, for 
when the volume of EAT by echocardiography or MRI is controlled for by VAT 
mass, there is no additional risk of CVD [69, 70].  However, it does appear that 
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perivascular fat surrounding small arteries from lean patients promotes 
vasodilation of the underlying artery [62, 65].  This beneficial effect is mediated 
by the paracrine effects of adiponectin which stimulates nitric oxide synthase in 
the adjacent endothelium.  These beneficial properties of PVAT are abrogated in 
obese patients, due to decreased adiponectin expression, increased expression 
of inflammatory cytokines, and increased reactive oxygen species.  Therefore, it 
appears that PVAT has a physiological function akin to other types of fat; 
beneficial in lean conditions but pathologic in obese conditions.  As we shall 
review in the next section, studies from mice have largely confirmed these 
findings. 
 
 Animal Studies 
     Studies of PVAT in mice are prone to several limitations: there are no models 
of PVAT deficient mice that have been described yet.  The genetic ablation of 
specific fat depots in mice is a technological hurdle that has yet to be achieved.  
Second, the small amount of PVAT in mice somewhat limits the experimental 
procedures that can be performed.  Nonetheless, in general, there is 
accumulating evidence that the function of PVAT in mice is much like that which 
has been described for humans; beneficial and protective in lean conditions and 
inflammatory and pathologic in obese conditions. 
     That PVAT has a vasodilatory effect was first shown by Soltis et al. in 1991 
when they demonstrated that intact PVAT prevented constriction of aortic rings in 
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response to epinephrine [71].  Since then, the majority of work regarding PVAT 
has been done in the field of hypertension, in search of the elusive “adipocyte 
derived relaxation factor” (ADRF), which was thought to act in an endothelium 
independent mechanism by direct activation of K+ channels on vascular smooth 
muscle [72].  This factor was recently identified by Lee et al. as palmitic acid 
methyl ester (PAME)[72].  PAME is released from the PVAT of Sprague Dawley 
rats and directly vasodilates aortic rings devoid of endothelium.  PAME release 
from the PVAT of spontaneously hypertensive rats is dramatically reduced, while 
Angiotensin II (ATII) release is increased.  The vasoconstrictor response to PVAT 
of hypertensive rats is inhibited by incubation with the ATII receptor blocker 
losartan [72].  Therefore, an endothelium independent vasodilator, PAME, is 
released from the PVAT of lean rats to promote dilation of smooth muscle.  
Whether or not other vasodilatory factors exist in rats or mice, such as 
adiponectin, which are dependent upon the endothelium, is an area of active 
investigation. 
          A previously cited study by Henrichot et al. showed that rats fed a HFD 
developed increased amounts of PVAT around the abdominal but not the 
thoracic aorta [61].  Interestingly, the abdominal, but not the thoracic aorta, is 
prone to aneurysm formation.  Obesity is an independent risk factor for the 
development of abdominal aortic aneurysm (AAA) formation [73].  Therefore, the 
authors concluded that growth of peri-aortic PVAT in the abdominal region of 
obese patients may contribute to aneurysm formation.   
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     A recent paper by Police et al. extended these findings by using a mouse 
model of AAA to study associated changes in PVAT [74].  Mouse were fed a 
HFD for 1-4 months and then infused with ATII via osmotic mini-pumps for 28 
days.  The incidence of aortic aneurysm increased with the duration of HFD[74].  
PVAT surrounding the abdominal aorta secreted greater amounts of Mcp-1 than 
PVAT surrounding the thoracic aorta.  Similarly, conditioned media from 
abdominal PVAT stimulated transwell migration of monocytes to a greater extent 
than conditioned media from PVAT surrounding the thoracic aorta.  Macrophages 
were seen infiltrating the abdominal PVAT, and the degree of macrophage 
staining correlated with AAA formation [74].  The authors concluded that 
increased chemokine secretion in the abdominal PVAT of obese mice may 
recruit macrophages which subsequently degrade the external elastic lamina of 
the aorta via secretion of matrix metalloproteinase, thus initiating AAA formation 
[74]. 
     In the absence of models which are devoid of PVAT, there have been a series 
of elegant papers which use removal and transplantation of PVAT to study 
disease in the associated vessel [75, 76].  Perhaps the most of definitive of these 
studies, was performed by Takaoka et al., using the mouse wire injury model[76].  
Wire injury of the mouse femoral artery stimulates neointimal hyperplasia, and is 
similar to the pathophysiology of in-stent restenosis after percutaneous 
intervention in humans.  The authors found that mice fed a HFD had reduced 
expression of adiponectin, and increased expression of Mcp-1, Tnfα, Il6, and Pai-
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1 in PVAT surrounding the femoral artery.  This was associated with increased 
macrophage infiltration of femoral PVAT in HFD mice as shown by Mac-3 
staining.  These changes translated into a large increase in neointima formation 
after wire injury in the HFD fed mice [76].  Removal of PVAT from lean mice also 
promoted wire injury neointimal hyperplasia after wire injury; in contrast, 
transplantation of SAT from lean mice prevented neointimal hyperplasia.  
Adiponectin alone applied to the vessel in the absence of PVAT prevented robust 
neointimal hyperplasia.  In vitro, adiponectin was subsequently shown to inhibit 
platelet derived growth factor (PDGF) stimulation of smooth muscle cell growth 
via AMP-activated protein kinase (AMPK).  This anti-proliferative effect of 
adiponectin is abrogated in the PVAT from obese mice.  These findings are 
highly clinically relevant to human disease, as obese diabetic patients have 
higher rates of in-stent restenosis following PCI, which may be due to reduced 
adiponectin secretion by epicardial fat [77]. 
     A second study used transplantation of VAT to the carotid artery of Apoe-/- 
mice to determine if inflammation in the perivascular fat depot could impact 
atherosclerosis [75]. Transplantation of VAT to the carotid artery worsened 
underlying atherosclerosis in the carotid artery, compared to arteries that 
received transplants of SAT. In addition, endothelium dependent relaxation of the 
underlying carotid artery was impaired when VAT was transplanted [75]. The 
observed increase in atherosclerosis could be prevented by whole body 
deficiency of P-Selectin glycoprotein ligand-1(Psgl-1) or antibodies to Psgl-1. 
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Although this is an artificial model of inflammation, it does suggest that 
inflammation in the adventitia can initiate atherosclerosis via activation of 
underlying vascular endothelium [75].  
     In summary, the data from human and mouse studies suggest that PVAT 
serves a beneficial function in lean conditions, to directly or indirectly vasodilate 
the underlying smooth muscle cells, or to restrain smooth muscle cell 
hyperplasia, both effects being mediated by adiponectin [65, 76].  Palmitic acid 
methyl ester is a second paracrine mediator secreted by PVAT which has direct 
vasodilatory effects on vascular smooth muscle, and there are likely many others 
which are yet undiscovered [72](Table 1.3). However, in obese conditions, 
perivascular adipocytes may hypertrophy, leading to the infiltration of 
macrophages, decreased adiponectin expression, and increased expression of 
pro-inflammatory cytokines such as TNFα, IL6, and MCP-1 (Figure 1.5). This has 
been observed to occur in human disease and mouse models of vascular 
disease [60, 61, 74, 78].  Whether or not inflammation in perivascular adipose 
tissue directly contributes to the development of atherosclerosis, peripheral 
vascular disease, or neointimal hyperplasia is a very intriguing hypothesis that 
has yet to be demonstrated.  
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TABLE 1.3. Vasocrine Mediators Released From PVAT  
Factor Context Source Effect 
Beneficial Factors    
Palmitic acid methyl 
ester[72] 
-released from PVAT of 
SD rats and mouse 
3T3L1 cells in culture 
-decreased release from 
PVAT of SH rats 
-perivascular 
adipocytes 
-vasodilation via direct 
stimulation of VSMC 
potassium channels  
Adiponectin[65] -released from lean 
human PVAT 
surrounding small 
arteries in SAT; 
expression reduced in 
obese humans 
-perivascular 
adipocyte? 
-endothelium dependent 
vasodilation 
Adiponectin[76] -released from PVAT 
surrounding femoral 
arteries of lean mice; 
expression reduced in 
obese mice 
-perivascular 
adipocytes 
-inhibition of vascular 
smooth muscle 
proliferation in vivo and in 
vitro via AMPK dependent 
pathway 
Leptin[79] -studied the response of 
SH rats to exogenous 
leptin 
-perivascular 
adipocytes? 
-endothelium dependent 
dilatation of conduit 
arteries 
Pathologic factors 
 
   
TNFα[65] -increased expression in 
PVAT surrounding small 
arteries from obese 
humans 
-perivascular 
adipocytes, or 
macrophages 
in PVAT 
-loss of vasodilator effect 
of PVAT; likely due to 
down regulation of NOS 
by TNFα 
Angiotensin II[72] -increased expression in 
the PVAT of SH rats 
-perivascular 
adipocytes 
-increased vaso-
constriction of aortic rings, 
blocked by incubation with 
ATIIR blocker 
Visfatin[80] -increased expression in 
SD rat PVAT 
-perivascular 
adipocytes 
-stimulation of vascular 
smooth muscle 
proliferation in vitro 
Resistin[64] -increased expression in 
PVAT from humans with 
ACS 
-macrophages 
in PVAT? 
-stimulates endothelial cell 
permeability in vitro 
Complement component 
3[81] 
-identified in proteomic 
analysis of PVAT from 
thoracic aorta of SD rats 
-perivascular 
adipocytes 
-stimulates differentiation 
and migration of 
adventitial myofibroblasts 
Secretory Type II 
Phospholipase A2 
-increased expression in 
EAT of patients with CAD 
-macrophages 
in PVAT 
-promotes formation of 
inflammatory lipid 
mediators in EAT 
SD=Sprague Dawley rat, SH=Spontaneously Hypertensive rate, EAT=epicardial adipose tissue, 
CAD=coronary artery disease, PVAT=perivascular adipose tissue, NOS=Nitric oxide synthase, 
VSMC=Vascular smooth muscle cell, ATIIR=angiotensin II receptor, ACS=acute coronary syndrome 
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Specific Aims 
     It is well established that VAT rather than SAT confers an increased risk of 
cardiovascular disease.  This is thought to be due to the propensity for increased 
VAT to cause insulin resistance.  Mechanisms by which VAT causes insulin 
resistance include increased rates of lipolysis, chronic inflammation, and fatty 
acid spillover from VAT to peripheral organs such as the liver and skeletal 
muscle.  The latter phenomenon, referred to as “lipotoxicity”, results in the 
clinically apparent manifestations of the metabolic syndrome which include: 
hyperglycemia, hypertriglyceridemia, low HDL cholesterol, and increased systolic 
blood pressure.  These risk factors in turn confer the excess cardiovascular risk 
associated with abdominal obesity. 
     The propensity for VAT to become inflamed, yet SAT to remain comparatively 
non-inflamed, has stimulated interest in the unique features of anatomically 
distinct fat depots in humans and mice.  Perivascular adipose tissue (PVAT) is 
one such depot.  PVAT has been proposed as a direct link between obesity and 
cardiovascular disease.  Therefore, we aimed to test the hypothesis that PVAT, 
like VAT, becomes inflamed in mouse models of obesity or vascular disease.  
The specific aims of our studies were:  
     To compare the degree of inflammation in PVAT and VAT in a mouse model 
of diet induced obesity. 
     To determine if inflammation in PVAT is associated with atherosclerosis in the 
apolipoprotein E knockout mouse. 
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CHAPTER II: Similarity of Mouse Perivascular and Brown Adipose Tissue 
and their Resistance to Diet Induced Inflammation 
 
 
Disclaimer:   
All experiments were performed by the author except for the following; Figure 2.4 
which was done by Greg Hendricks; Figure 2.8 which was done by Sophia 
Kogan;  Figures 2.6 and 2.7 were done by the Morphology Core and the 
microarray hybridizations by the Genomics Core of the Diabetes and Endocrine 
Research Center (DK-32520).  Jeurg Straubhaar uploaded the microarray data to 
MACE and performed detailed statistical analyses. 
 
 
 
 
This chapter is in the format published:  
Timothy P. Fitzgibbons, Sophia Kogan, Myriam Aouadi, Greg M. Hendricks, 
Jeurg Straubhaar, and Michael P. Czech.  Similarity of mouse perivascular and 
brown adipose tissues and their resistance to diet-induced inflammation.  Am J 
Physiol Heart Circ Physiol 301: H1425-H1437, 2011. 
43 
 
Abstract 
      Thoracic PVAT is a unique adipose depot that likely influences vascular 
function and susceptibility to pathogenesis in obesity and metabolic syndrome. 
Surprisingly, PVAT has been reported to share characteristics of both brown and 
white adipose, but a detailed direct comparison to inter-scapular BAT has not 
been performed. Here we show by full genome DNA microarray analysis that 
global gene expression profiles of PVAT are virtually identical to BAT, with 
equally high expression of uncoupling protein 1 (Ucp-1), cell death-inducing 
DFFA-like effector A (Cidea) and other genes known to be uniquely or very highly 
expressed in BAT. PVAT and BAT also displayed nearly identical phenotypes 
upon immunohistochemical analysis, and electron microscopy confirmed that 
PVAT contained multi-locular lipid droplets and abundant mitochondria. 
Compared to white adipose tissue (WAT), PVAT and BAT from C57BL6/J mice 
fed a high fat diet for 13 weeks had markedly lower expression of immune cell-
enriched mRNAs, suggesting resistance to obesity induced inflammation.  
Indeed, staining of BAT and PVAT for macrophage markers (F4/80, CD68) in 
obese mice showed virtually no macrophage infiltration, and FACS analysis of 
BAT confirmed the presence of very few CD11b+/CD11c+ macrophages in BAT 
(1.0%) in comparison to WAT (31%).   In summary, murine PVAT from the 
thoracic aorta is virtually identical to inter-scapular BAT, is resistant to diet 
induced macrophage infiltration, and thus may play an important role in 
protecting the vascular bed from inflammatory stress. 
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Introduction 
     The burgeoning prevalence of obesity and diabetes throughout the world 
threatens to accelerate the incidence of associated cardiovascular diseases, 
including coronary artery disease, hypertension, and congestive heart failure.  
Although the mechanism by which obesity causes vascular disease is not fully 
understood, insulin resistance and the  metabolic syndrome are thought to play a 
major role [8, 13, 82, 83].  In human obesity as well as mouse models of obesity, 
enlarged adipocytes in visceral adipose tissue become insulin resistant  and fail 
to effectively store excess triglyceride through decreased capacity for lipogenesis 
and increased lipolysis [8, 12, 13, 84, 85].   These changes in adipose function 
lead to infiltration of immune cells, which are thought to cause chronic low grade 
inflammation in obese subjects with the metabolic syndrome [13, 86].  Lipid 
overload in the face of decreased capacity of adipocytes to store triglycerides 
leads to ectopic lipid deposition in liver and muscle resulting in systemic insulin 
resistance [13, 34].  Prolonged obesity with these associated disorders is thought 
to be the major cause of beta cell failure and type 2 diabetes in humans. 
     It is now well established that expansion of VAT, rather than SAT, confers a 
high risk for the metabolic syndrome and incident cardiovascular disease [8, 82, 
87].  Hypotheses for this observation include: increased expression of 
angiotensinogen and complement, a greater rate of monocyte infiltration, and 
increased IL6 secretion in VAT compared to SAT [54].  It has also been 
postulated that the elevated rates of lipolysis in VAT compared to SAT render the 
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former less able to sequester triglycerides away from liver and muscle [88].   
These and other important differences between VAT and SAT have stimulated 
interest in the discovery of additional adipose depots which might have similar or 
increasingly pathologic functions in obesity.  One such adipose depot is 
perivascular adipose tissue (PVAT), which was recently proposed to be a 
potential link between diabetes and cardiovascular disease [61, 65, 74, 76, 89].  
The outermost connective tissue or adventitia surrounding an artery, including 
PVAT, may be prone to the same inflammation as VAT, and the idea that 
vascular disease could be impacted and perhaps promoted by factors in the 
adventitia has long-standing support [55-58].  
     Initial studies of PVAT from human coronary arteries surprisingly detected 
expression of some BAT-specific genes (PR domain containing 16 (PRDM16), 
UCP-1, carnitine palmitoyl transferase 1B (CPT1B)) to a degree that appeared 
intermediate to white and brown adipose tissues [89].  These studies suggested 
PVAT might be an example of the recently described “brite” adipose tissue—
white adipose that retains many of its usual characteristics but also displays 
some expression of BAT genes, including Ucp-1 [90]. Interestingly, in rodents, 
PVAT surrounding the abdominal aorta displays characteristics of white adipose 
tissue, whereas PVAT surrounding the thoracic aorta appears quite different, and 
is known to express some BAT genes [74, 91].  Although thoracic PVAT showed 
similarities to BAT in morphology and expressed Ucp-1, a direct detailed 
genomic comparison to true inter-scapular BAT has not yet been made [74, 91]. 
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The extent to which thoracic PVAT in mice is more similar to human coronary 
PVAT, which displays only partial similarity to BAT, or to true inter-scapular BAT 
is an important question since mice are frequently used as models of human 
cardiovascular disease.  
     We addressed this question by directly comparing genome wide expression of  
thoracic PVAT to brown and white adipose depots from mice fed a normal or high 
fat diet for 13 weeks.  Remarkably, PVAT and BAT had virtually identical gene 
expression profiles. Furthermore, in comparison to the infiltration of macrophages 
into VAT of obese mice and the increased expression of macrophage enriched 
genes in this tissue, thoracic PVAT and BAT were strikingly resistant to 
inflammation induced by high fat feeding, as shown by microarray, 
immunohistochemistry, and FACS analysis.  We conclude that PVAT 
surrounding the murine thoracic aorta is virtually identical to inter-scapular BAT, 
and like BAT is resistant to inflammation under HFD conditions.  
Experimental Procedures 
Animal Studies- Male C57BL6/J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME).  All animals were fed normal chow until 8 weeks of 
age.  Animals were then divided into two groups; one fed normal chow and one 
fed high fat diet (45 kcal% fat, D12451 Research Diets) for 13 or 20 weeks. 
Animals were fed ad libitum with free access to water and housed in the UMASS 
Animal Medicine facility with a 12:12 light dark cycle.  Animals were weighed 
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weekly for the duration of the diet study.   Intraperitoneal (i.p.) glucose tolerance 
testing (GTT) was performed as previously described [92].  Area under the curve 
for the GTT was calculated using the trapezoidal method [92].  At the completion 
of the high fat diet,  mice were fasted for 6 hours and  then euthanized with CO2 
inhalation and bilateral pneumothorax.  SAT (inguinal), VAT (epididymal) and 
BAT(inter-scapular)  were harvested and snap frozen in liquid nitrogen.    Blood 
was drawn via cardiac puncture into heparin coated tubes and the circulatory 
system was perfused with ice cold PBS.  Thoracic PVAT directly adjacent to the 
lesser curvature of the aortic arch was then harvested and snap frozen in liquid 
nitrogen.  All experiments were performed in accordance with protocols approved 
by the Animal Care and Use Committee at UMASS Medical School.   
Insulin levels- Blood was collected via cardiac puncture at the time of euthanasia 
into heparin coated microcentrifuge tubes and centrifuged at 3000 x g for 15 
minutes.  Serum was then decanted and stored at -80 °C.  Fasting insulin levels 
were measured in duplicate with 10 μl of serum using a Rat/Mouse Insulin ELISA 
(Millipore, St. Charles, MO) according to the manufacturers’ instructions. 
Quantitative PCR- Adipose tissue was isolated as previously described, snap 
frozen in liquid nitrogen and stored at -80°C.  Tissues were homogenized and 
total RNA was isolated with RNA Mini Lipid kits (Qiagen, Valencia, CA).  250 ng 
total RNA was reverse transcribed with the Bio-Rad iScript cDNA Synthesis Kit 
(Bio-Rad, Hercules, CA).  cDNA was diluted 1:5 and 2.5 μl was used in a 12.5 μl 
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reaction volume; each reaction was performed in duplicate.  Real time qPCR was 
performed with a Bio-Rad C1000 Thermal Cycler and SYBR Green Master Mix 
(Bio-Rad, Hercules, CA) using the following cycle parameters: 95.0° C for 3 min, 
95.0° for 0:10 min, 60.0° C for 0:15 min, 72.0° C for 0:30 min for 40 cycles.  
Expression was normalized to the reference gene 36b4 and expressed as 
relative to expression in SAT of normal diet mice using the 2 –ΔΔct method [93].  
Melt curve analysis and agarose gel electrophoresis was performed to determine 
the specificity of the PCR reaction products.  Primer sequences were: Ucp-1 for  
AGGCTTCCAGTACCATTAGGT, Ucp-1 rev CTGAGTGAGGCAAAGCTGATTT,  
Acrp30  for TGTTCCTCTTAATCCTGCCA and Acrp30 rev 
CCAACCTGCACAAGTTCCCTT, 36b4 for TCCAGGCTTTGGGCATCA, 36b4 rev 
CTTTATCAGCTGCACATCACTCAGA, Cidea for 
ATCACAACTGGCCTGGTTACG, Cidea rev TACTACCCGGTGTCCATTTCT, 
PPARγ2 for ATGGGTGAAACTCTGGGAG, and PPARγ2 rev 
GTGGTCTTCCATCACGGAGA. 
Microarray Analysis- RNA was isolated from SAT, VAT, BAT, and PVAT as 
previously described.  RNA concentrations were determined using a Nanodrop 
2000 Spectrophotometer (Thermo Fisher, Willmington, DE).  The RNA quality 
was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA).  Only samples with a RNA Integrity Number >7.5 and normal 18 and 
28s fractions on microfluidic electrophoresis were used.  RNA from two mice per 
tissue and diet was pooled for a total of 250 ng total RNA template for cDNA 
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synthesis and in vitro transcription using the Ambion WT Expression kit (Ambion, 
Carlsbad, CA).  Second strand cDNA was then labeled with the Affymetrix WT 
Terminal Labeling kit and samples were hybridized to Affymetrix Mouse Gene 1.0 
ST arrays (Affymetrix, Santa Clara, CA).  Gene chip expression array analysis for 
individual genes was performed as previously described [94], filtering for p <0.05 
and a fold change of >2.  Three biological replicate hybridizations per tissue and 
diet were performed, for a total of 24 hybridizations.      Robust multi-array 
average (RMA) was adopted in the UMASS Microarray Computational 
Environment (MACE) to preprocess raw oligonucleotide microarray data. The 
algorithm was implemented as a function of the R package Affy [95], which is 
part of the Bioconductor project [96] using the statistical computing language R 
(R Foundation for Statistical Computing, Vienna, Austria).  All statistical 
calculations are performed using the R statistical computing environment and 
results are stored in a relational database.  The preprocessed data are stored as 
base 2 log transformed real signal numbers and are used for fold-change 
calculations and statistical tests and to determine summary statistics. Mean 
signal values and standard deviations are computed for each gene across 
triplicate experiments and stored in the database. The fold change of expression 
of a gene in two experiments is the ratio of mean signal values from these 
experiments and is always a number greater than one. If the ratio is less than 
one, the negative value of the inverse ratio is stored as fold change. All down 
regulated genes therefore have a negative fold change value, up regulated 
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genes have a positive fold change. In both cases this value is greater or equal 
than one. 
     To determine differential expression of genes in two hybridization experiments 
MACE internally conducts a Student’s t-test with the expression signal values of 
the two hybridizations for all genes in the set. The t-test value and test p-value 
are stored in MACE and can be queried through the MACE user interface. The p-
values stored and displayed as a result of a query are not adjusted for multiple 
testing.  The data discussed in this publication have been deposited in NCBI’s 
Gene Expression Omnibus [97] and are accessible through GEO Series 
accession number GSE28440 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28440).  
Histology and Immuno-histochemistry- Adipose tissue samples (n=3 per group) 
from normal and high fat diet animals were fixed in 4% formalin for 
immunohistochemistry.  Briefly, samples were embedded in paraffin, sectioned, 
and stained with a rat anti-mouse F4/80 (ABd Serotec, Raleigh, NC)(1:50 
dilution) or rat anti-mouse CD68 primary antibody (ABd Serotec, Raleigh, 
NC)(1:40 dilution).  Staining was visualized with a HRP linked rabbit anti-rat 
secondary anti-body.  Staining with the secondary antibody alone was performed 
as a negative control.  Images were taken with a Zeiss Microscope and PixeLINK 
SE Software. 
Transmission electron microscopy of adipose tissue samples- Adipose tissue 
samples were fixed in 2.5% glutaraldehyde in PBS (pH 7.2).   Tissue samples 
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were dissected into 1 mm blocks and the tissues washed three times and left 
overnight in fresh buffer.  The next morning the samples were post-fixed for 1 hr 
in 1% osmium tetroxide.  The fixed adipose tissue samples were then washed 
again in the PBS and dehydrated through a graded series of ethanol to 100% 
and transferred through two changes of propylene oxide and finally into a 50:50  
(v/v)mixture of  propylene oxide: epoxy resin (SPON 812/Araldite 502 ) and left 
overnight to infiltrate.  The following morning the adipose tissue samples were 
processed through two changes of fresh epoxy resin and embedded, allowing the 
blocks to polymerize 48 hrs at 70°C.  Blocks of tissue were then selected, cut out 
and attached to blank epoxy stubs with a drop of Super Glue.  Ultrathin sections 
were cut on a Reichart-Jung ultramicrotome using a diamond knife.  The 
sections  (64 nm thick) were collected and mounted on copper support grids and 
contrasted with lead citrate and uranyl acetate and examined on a Philips CM 10 
transmission electron microscope at 80 Kv accelerating voltage.   
FACS Analysis- Mice were euthanized and BAT and VAT was removed and 
treated with 4 mg/mL and 2 mg/mL collagenase respectively in 4% BSA in PBS 
at pH=7.4 for 1 hour. Samples were filtered through 200μM and 30 μM spectra 
mesh sequentially and stained with CD31 (BD Biosciences, Franklin Lakes, NJ; 
1:1000 dilution), CD11b (BD Biosciences, Franklin Lakes, NJ; 1:200 dilution) and 
CD11c (BD Biosciences, Franklin Lakes, NJ; 1:200 dilution) according to the 
manufacturer’s instructions. Samples were run on a BD LSRII flow cytometer (BD 
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Biosciences, Franklin Lakes, NJ) and analyzed in Flow Jo, gating for CD31 
negative cells.  
Statistical Analysis- All values are shown as mean ± SEM.  For experiments 
other than the microarray analyses, the Student’s t test for two tailed distributions 
with equal variances was used for comparison between 2 groups; for 
comparisons greater of ≥ 3 groups, two way ANOVA followed by the Bonferroni 
correction was used.   Differences less than p ≤ 0.05 were considered significant.  
Data was entered into Microsoft Excel and statistical analyses were performed 
with Graph Pad Prism 5. 
Results 
Cidea and Ucp-1 are highly expressed in BAT and PVAT independent of 
obesity. 
     HFD mice (n=12) gained more weight than ND mice (n=12) beginning at 3 
weeks and remained significantly more obese until the end of the study (30.9 ± 
0.75 vs. 42.08 ± 0.78 gms p<0.001)(Fig 2.1A).  At the end of 13 weeks, HFD 
mice were more glucose intolerant as shown by an elevated fasting blood 
glucose concentration (136.4 ± 1.22 vs. 185.8 ± 21.4 mg/dL p<0.02), elevated 
fasting insulin levels (2.1 ± 0.64 vs. 5.4 ± 1.03 ng/mL p<0.02), and increased 
area under the curve for the IPGTT ((min*mg/dL) =29352 ± 753 vs. 38983 ± 1928 
p<0.01)(Fig 2.1B). 
53 
 
    Analysis of mRNA from adipose tissue samples by qPCR showed that Cidea 
and Ucp-1 were highly expressed in PVAT and BAT compared to SAT.  
Remarkably, the relative expression between these two depots was similar for 
both genes (Fig 2.2A,B).  Interestingly, Cidea expression was reduced >50% by 
HFD in both PVAT and BAT; this effect was not observed for Ucp-1 (Fig 2.2A,B).  
With respect to other markers of adipose differentiation, PPARγ2 expression was 
slightly greater in VAT, PVAT, and BAT than SAT and significantly reduced by 
HFD in these depots (Fig 2.2D).  Adiponectin (Acrp30) expression was 
significantly greater in VAT and decreased with HFD (Fig 2.2C); expression of 
this gene was similar in all other depots.  Therefore, PVAT expresses Cidea and 
Ucp-1 to an equivalent degree as BAT, suggesting that it may be more similar to 
BAT than “brite” adipose tissue.  Furthermore, it is responsive to HFD and not 
different from other adipose depots with respect to makers of adipose 
differentiation, such as PPARγ2 and Acrp30.   
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FIGURE 2.1. Thirteen weeks of HFD results in obesity, glucose 
intolerance and hyperinsulinemia in C57BL6/J Mice.  (A)  Growth 
curves of normal diet (n=12, dashed line) and high fat diet mice (n=12, 
solid line).  Weights were significantly different at all time points after 3 
weeks. Data points are mean ± SEM.  *p<0.05 vs. ND using the Student’s 
t test.  (B) Intraperitoneal glucose tolerance test from C57BL6/J mice fed 
normal (n=12, dashed line) or high fat diet (n=12, solid line) for 13 weeks.  
Results are mean ± SEM.  *p<0.05 vs. ND using the Student’s t test.  
(Inset)  Fasting insulin levels in normal (n=12, white) and high fat diet mice 
(n=12, black).  Results are mean ± SEM.  *p<0.05 vs. ND using the 
Student’s t test.    
 
A B 
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FIGURE 2.2. Cidea and Ucp-1 are highly expressed in BAT and PVAT 
independently of obesity.  (A,B,C,D) Cidea, Ucp-1, Pparγ2 and Acrp30 
expression in normal and high fat diet mice.  qPCR was performed on total 
RNA isolated from inguinal (SAT), epididymal (VAT), inter-scapular brown 
(BAT) and perivascular adipose from the aortic arch (PVAT).  Expression 
levels were calculated with the 2-ΔΔct method using 36b4 as the reference 
gene and normalized to expression in SAT from normal diet conditions.  
Ucp-1 expression is shown in log10 scale.  (ND n=12 white, HFD   n=12, 
black) Results are mean ± SEM.  *** p<0.001 vs. SAT ND, # p<0.05 ND 
vs. HFD of the same fat depot using two way ANOVA and the Bonferonni 
correction.   
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Mouse Thoracic PVAT is morphologically similar to BAT. 
     In order to test the hypothesis that thoracic PVAT is virtually identical to inter-
scapular BAT, we performed microscopic analysis of these adipose depots.  As 
judged by light microscopy on hematoxylin and eosin stained sections of PVAT 
and BAT under ND and HFD conditions, PVAT appeared very similar to BAT, 
with round nuclei, and small, multi-locular lipid droplets (Fig 2.3G). The majority 
of PVAT surrounding the thoracic aorta had the appearance of BAT, with small 
areas of adipose tissue resembling WAT (Fig 2.3G).  BAT lipid droplet 
architecture was obviously distorted by 13 weeks of HFD, with enlargement and 
coalescence of lipid droplets (Fig 2.3F). Surprisingly, this effect was not apparent 
in PVAT, although it did occur with a longer duration of HFD. 
     Transmission electron microscopy confirmed the BAT phenotype of thoracic 
PVAT, and detected some interesting differences compared to inter-scapular 
BAT (Fig 2.4).  Both PVAT and BAT from mice fed ND were densely packed with 
mitochondria and had multi-locular lipid droplets which were darkly stained with 
osmium tetroxide (Fig 2.4A, C). Interestingly, lipid droplets in BAT tended to lose 
their avidity for osmium when obtained from mice after high fat feeding, mostly 
appearing white (Fig 2.4B). This effect was not observed in PVAT (Fig 2.4D).  
High fat feeding resulted in significant mitochondrial swelling and unfolding of 
cristae in PVAT (Fig 2.4D), which was not apparent in BAT at this time point, but 
visible after a longer duration of HFD (Data not shown).  These observations 
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correlated with changes in gene expression.  For example, Fads1 was 
significantly down regulated (-1.82) in BAT compared to PVAT in HFD conditions.  
Likewise, a search for alterations in the expression of mitochondrial genes 
revealed that expression of the pro-apoptotic gene Bid and mitochondrial solute 
carrier genes Slc25a35 and Slc25a37 were up regulated in PVAT compared to 
BAT in HFD conditions; a third member of this latter gene family, the calcium 
binding carrier protein Aralar1(Slc25a12), was significantly up regulated in BAT 
compared to PVAT (2.58 FC, p=0.002).  Therefore, thoracic PVAT and BAT 
appear virtually identical upon analysis by both light and electron microscopy, 
with the exception of subtle differences in lipid droplet and mitochondrial 
morphology, which correlate with changes in gene expression.   
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 FIGURE 2.3. Perivascular adipose tissue appears morphologically similar 
to brown adipose tissue.  Fat was harvested from subcutaneous, visceral, 
inter-scapular brown  and perivascular adipose tissue from the lesser curvature 
of the aortic arch from normal and high fat diet fed mice and then fixed in 
formalin.  Tissues were stained with hematoxylin and eosin and visualized at 25x.  
Images G and H are low magnification images (6.3x) of I and J.  (Ao=aortic 
lumen)  
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FIGURE 2.4.  Transmission electron microscopy reveals many similarities 
between perivascular and brown adipose tissues.  Sections of brown (A,B) 
and perivascular adipose (C,D) were taken and stained with osmium tetroxide.  
In normal diet conditions, brown (A) and perivascular adipose (C) appear very 
similar with multi-locular lipid droplets and abundant mitochondria.  Two 
prominent changes were noted in high fat feeding conditions; lipid droplets in 
brown adipose tissue, but not perivascular, lose their avidity for osmium tetroxide 
(B), and mitochondria become swollen with unfolded cristae (D); the latter effect 
was more prominent in perivascular adipose but also observed in brown adipose 
after a  longer duration of HFD. (Magnification 7900x, scale bar= 2 microns, 
LD=lipid droplet, M=mitochondria, EC=endothelial cell, RBC=red blood cell) 
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Microarray analysis confirms PVAT has a characteristic brown adipose 
gene expression signature. 
     To validate and expand the above findings, DNA microarrays were used to 
contrast global differences in gene expression between adipose depots from 
mice under control and high fat feeding conditions.  Total RNA was hybridized to 
Affymetrix Mouse Gene 1.0 ST chips, each of which contains probes targeting 
28,853 genes.  Analysis of the full genome set of gene expression differences 
among the four adipose depots showed high similarity of PVAT to BAT, and a 
much greater divergence of gene expression when compared to white adipose 
depots (SAT,VAT)(Figure 2.5, Table 2.1, Supplementary Tables S1-4).  When 
comparing PVAT to BAT in normal diet conditions, only 228 genes demonstrated 
significantly different expression (Fig 2.5, Supplemental Table S3).  With regard 
to the specific genes which were differentially expressed, in comparison to BAT, 
PVAT had greater expression of immunoglobulin genes (IgK, Igh-6), complement 
(Cfh, C7), and mast cell specific genes (Mcpt4)(Supplemental Table S3).  In 
contrast, the vast majority of genes whose expression was greater in BAT than 
PVAT were related to skeletal muscle differentiation and function (Supplemental 
Table S3).   Interestingly, additional genes expressed to a greater extent in BAT 
than PVAT were highlighted by the mesodermal developmental genes Tbx15 
(3.8 fold), Myf6 (3.2 fold), and Zic1 (2.1 fold)(Supplemental Table S3). 
61 
 
     Next, we refined this analysis by comparing gene expression differences in 
PVAT relative to BAT and SAT from mice fed ND with respect to selected 
specific gene categories (Table 2.1).    Strikingly, there were no significant 
differences between PVAT and BAT in levels of expression of any genes known 
to be highly expressed in brown adipocytes (Table 2.1).  Nor were there any 
differences between PVAT and BAT under ND conditions in the expression of the 
majority of specific genes examined, with the exception of Fads1 (Table 2.1).  In 
contrast to these virtually identical gene expression profiles between PVAT and 
BAT, highly significant decreases in expression were displayed by brown 
adipocyte enriched genes in SAT and VAT compared to PVAT (Table 2.1).  As 
expected, expression of white adipose enriched genes was significantly greater 
in SAT and VAT compared to PVAT (Table 2.1).  In other gene categories, 
expression of the adipokines Lep, Retn, Rbp4, and Adipoq was higher in SAT 
and VAT, whereas the receptors for Adipoq (Adipor1/Adipor2) were more highly 
expressed in PVAT (Table 2.1).  In regards to lipid metabolism genes, those 
involved in synthesis or storage (Fads1, Fads3, Cidec) were expressed to a 
greater extent in SAT and VAT, whereas those functioning in lipid oxidation 
(Gpam, Acss1, Acsl5) were more highly expressed in PVAT and BAT (Table 2.1).  
Surprisingly, expression of immune cell enriched genes, such as chemokines 
(Ccl5, Ccl8), T cell receptors (Cd3g, Cd3d), and macrophage markers (Cd68, 
Emr1) was significantly greater in SAT and VAT compared to PVAT and BAT 
even under ND conditions (Table 2.1).  Given this dramatic difference in 
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expression of immune cell genes in white compared to brown adipose depots, we 
compared the effects of high fat feeding on changes in expression of immune cell 
enriched genes in the four adipose depots. 
     Shown in Table 2.2 are the fold changes in expression for a series of selected 
immune cell enriched genes when comparing ND to HFD conditions in PVAT, 
BAT, SAT and VAT depots.  VAT demonstrated the greatest fold increase in 
expression of immune cell genes after high fat feeding (Table 2.2).  Although the 
other depots exhibited some trends for changes in gene expression between ND 
and HFD fed mice, none of them met statistical significance (Table 2.2).    Taken 
together, the data in Figure 2.5 and Tables 2.1 and 2.2 reveal a remarkably 
similar global gene expression profile between PVAT and BAT. These two 
adipose depots show no significant differences in expression in the majority of 
genes previously shown to be enriched in brown adipocytes, white adipocytes or 
immune cells.  In addition, the data in Table 2.2 is particularly revealing in that 
the levels of expression of immune cell genes, as reflected by their probe set 
signals, is uniformly higher in both SAT and VAT compared to PVAT and BAT in 
both ND and HFD conditions. These data imply that the PVAT and BAT depots 
are relatively resistant to inflammation induced by high fat feeding compared to 
WAT depots.   
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FIGURE 2.5. Microarray analysis reveals that PVAT is more similar to BAT 
than SAT or VAT.  The MACE database was queried in ND and HFD conditions 
for genes with a >2.0 fold change in expression at P<0.05 level of significance 
between adipose depots.  In normal diet conditions, PVAT was very similar to 
BAT, with differential expression of only 228 genes (0.79% of genes); in contrast, 
expression of 1229 genes was differentially regulated when comparing PVAT 
and SC (4.2% of genes).  After high fat feeding, PVAT became more similar to 
white adipose, as the number of genes differentially regulated between PVAT 
and SC was reduced to 855 (2.9% of genes). 
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 PVAT vs. SAT PVAT vs. VAT PVAT vs. BAT 
Symbol FC P value FC P value FC P value  
Most Highly Enriched Genes 
Ucp1 21.6 <0.001 31.2 <0.001 1.0 NS 
Elovl3 19.3 <0.001 29.3 <0.001 1.1 NS 
Slc27a2 17.9 <0.001 17.2 <0.001 1.4 NS 
Cox7a1 16.1 <0.001 23.1 <0.001 1.0 NS 
Cpt1b 14.5 <0.001 24.7 <0.001 1.0 NS 
Kng2 14.0 <0.001 12.4 <0.001 1.2 NS 
Acot11 12.6 <0.001 15.8 <0.001 1.0 NS 
Cidea 12.6 <0.001 31.8 <0.001 1.1 NS 
Brown adipose-enriched genes 
Ucp1 21.6 <0.001 31.2 <0.001 1.0 NS 
Elovl3 19.3 <0.01 29.2 <0.001 1.1 NS 
Slc27a2 17.8 <0.001 17.1 <0.001 1.4 NS 
Cox7a1 16.1 <0.001 23.0 <0.001 1.0 NS 
Cpt1b 14.5 <0.001 24.7 <0.001 1.1 NS 
Cidea 12.6 <0.001 31.7 <0.001 1.1 NS 
Dio2 8.0 <0.001 9.9 <0.001 -1.1 NS 
Prdm16 1.8 <0.001 2.41 <0.001 1.0 NS 
White adipose-enriched genes 
Hoxc8 -9.7 <0.001 -17.7 <0.001 2.1 NS 
Apol7c -8.2 <0.01 -1.6 NS 1.2 NS 
Dapl1 -6.3 <0.01 -2.0 NS 1.8 NS 
Nnat -6.1 <0.01 -6.9 <0.01 1.1 NS 
Sncg -4.2 <0.01 -5.5 <0.001 1.0 NS 
Stap1 -4.7 <0.05 -1.4 NS 2.9 NS 
Grap2 -3.9 <0.01 -1.4 NS 1.5 NS 
Mest -3.8 <0.01 -14.2 <0.001 1.0 NS 
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TABLE 2.1. Depot specific expression of select gene categories in normal diet conditions. 
Immune cell-enriched genes 
Symbol FC P value FC P value FC P value  
Most Highly Enriched Genes 
Ucp1 21.6 <0.001 31.2 <0.001 1.0 NS 
Elovl3 19.3 <0.001 29.3 <0.001 1.1 NS 
Slc27a2 17.9 <0.001 17.2 <0.001 1.4 NS 
Table 1: 
Depot 
specific 
express
ion of 
select 
gene 
categori
es in 
normal 
diet 
conditio
ns. 
Cox7a1 
16.1 <0.001 23.1 <0.001 1.0 NS 
Cpt1b 14.5 <0.001 24.7 <0.001 1.0 NS 
Kng2 14.0 <0.001 12.4 <0.001 1.2 NS 
Acot11 12.6 <0.001 15.8 <0.001 1.0 NS 
C dea 12.6 <0.001 31.8 <0.001 1.1 NS 
Brown adipose-enriched genes 
Ucp1 21.6 <0.001 31.2 <0.001 1.0 NS 
Elovl3 19.3 <0.01 29.2 <0.001 1.1 NS 
Slc27a2 17.8 <0.001 17.1 <0.001 1.4 NS 
Cox7a1 16.1 <0.001 23.0 <0.001 1.0 NS 
Cpt1b 14.5 <0.001 24.7 <0.001 1.1 NS 
Cidea 12.6 <0.001 31.7 <0.001 1.1 NS 
Dio2 8.0 <0.001 9.9 <0.001 -1.1 NS 
Prdm16 1.8 <0.001 2.41 <0.001 1.0 NS 
White adipose-enriched genes 
Hoxc8 -9.7 <0.001 -17.7 <0.001 2.1 NS 
Apol7c -8.2 <0.01 -1.6 NS 1.2 NS 
Dapl1 -6.3 <0.01 -2.0 NS 1.8 NS 
Nnat -6.1 <0.01 -6.9 <0.01 1.1 NS 
Sncg -4.2 <0.01 -5.5 <0.001 1.0 NS 
Stap1 -4.7 <0.05 -1.4 NS 2.9 NS 
Grap2 -3.9 <0.01 -1.4 NS 1.5 NS 
Mest -3.8 <0.01 -14.2 <0.001 1.0 NS 
       
       
Immune cell-enriched genes 
Il7r -5.7 <0.01 -1.3 NS 2.4 NS 
Ccl5 -5.6 <0.05 -1.3 NS 1.6 NS 
Cd3g -5.0 <0.01 -1.7 NS 2.3 NS 
Ccl8 -4.1 <0.01 1.0 NS -1.3 NS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ta le 1: Depot specific expression of select gene categories in 
normal diet conditions  
*The eight most highly up-regulated genes in PVAT vs. SAT in normal 
diet conditions  were ranked in descending order.  Expression levels of 
the same genes in PVAT vs. VAT and PVAT vs. BAT in normal diet 
c nditions were then queried, and are entered in the last two columns 
for comparison.  Expression of genes from select categories was also 
queried in normal diet conditions, and ranked according in descending 
order according to expression in SAT.  Genes with significantly 
increased expression in PVAT are in bold and genes with significantly 
decreased expression in PVAT are italicized.   
 
 
Il7r -5.7 <0.01 -1.3 NS 2.4 NS 
Ccl5 -5.6 <0.05 -1.3 NS 1.6 NS 
Cd3g -5.0 <0.01 - .7 NS 2 3
Ccl8 -4.1 <0.01 1.0 NS - .3 
Ccr7 -4.0 <0.05 -1.3 NS 
Cd3d -3.  <0.05 -1.2 NS - .1 
d68 -2.3 <0.05 -1.9 <0.05 - .3 
Emr1 -2.1 <0.05 - .3 <0.01 - .3 
Fatty acid biosynthesis and metabolism 
Fa s3 - .5 <0.01 -4.5 - .  
Fads1 1.5 NS -1.8 <0.01 -1.7 <0.05 
Cidec - .1 <0.05 - .6 <0.01 - .3 
Scd1 -1.0 NS -1.0 NS 0
Fasn -1.5 NS -1.5 NS 0
Gpam 2.6 1.4 <0.01 
Acss1 3.2 4.9 
Acsl5 3.7 4.2 
Adipokin  and r lated effector genes 
Lep -2.7 <0.05 -4.6 <0.01 - .3 
Retn -1.8 <0.001 -2.1 <0.001 -1.8 NS 
IL6st 1 4 -1.4 <0.01 -1.2 
Rbp4 1 4 5 2 3 <0.001 - .0 
Adi oq 1 5 1 6 <0.01 - .1 
T f ip6 1 3 5 1 2 5 - .0 
Adipor1 1.3 1.1 <0.05 - .  
Adi or2 1.4 1 1 0
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*The eight most highly up-regulated genes in PVAT vs. SAT in normal diet conditions were ranked in descending 
order.  Expression levels of the same genes in PVAT vs. VAT and PVAT vs. BAT in normal diet conditions were 
then queried, and are entered in the last two columns for comparison.  Expression of genes from select categories 
was also queried in normal diet conditions, and ranked according in descending order according to expression in 
SAT.  Genes with significantly increased expression in PVAT are in bold and genes with significantly decreased 
expression in PVAT are italicized.  NS=non-significant 
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TABLE 2.2.  Comparative expression of immune cell enriched genes in VAT, SAT, PVAT, and 
BAT in normal and high fat diet conditions.   
Querying the MACE dataset for genes with the greatest fold increase in expression from normal to 
high fat diet conditions, showed that VAT had the greatest increase in expression of inflammatory 
genes.  The same probe sets showed non-significant increases in SAT, and much smaller signals in 
PVAT and BAT.  Bold face, italicized genes are significantly up regulated. NS=non significant. 
 
 SAT VAT PVAT BAT 
Symbol ND HFD FC P ND HFD FC P ND HFD FC P ND HFD FC P 
Il7r 2038 1299 -1.5 NS 268 2779 10.4 <0.001 178 350 1.9 NS 62 164 2.6 NS 
Tlr13 564 531 -1.1 NS 397 2404 6.0 <0.001 133 343 2.6 NS 151 243 1.6 NS 
Il1rn 444 499 1.1 NS 367 1923 5.2 <0.001 220 403 1.8 NS 208 269 1.2 NS 
Cd84 665 574 -1.2 NS 426 2079 4.9 <0.001 128 281 2.2 NS 92 171 1.9 NS 
Mpeg1 1527 1292 -1.2 NS 713 3311 4.6 <0.001 240 555 2.3 NS 233 520 2.2 NS 
Cd68 2434 2160 -1.1 NS 2097 6895 3.3 <0.001 586 1451 2.5   NS 500 914 1.8 NS 
Ccl3 303 329 1.1 NS 207 662 3.2 <0.001 111 194 1.7 NS 116 182 1.6 NS 
Emr1 1247 1177 -1.1 NS 1276 3800 3.0 <0.001 283 604 2.1 NS 242 475 2.0 NS 
Ccl2 536 556 1.0 NS 546 1174 2.1 <0.05 158 225 1.4   NS 138 185 1.3 NS 
Ccl9 1457 1691 1.1 NS 1529 3262 2.1 <0.01 347 780 2.2 NS 249 467 1.8 NS 
Tnfrsf1b 911 735 -1.2 NS 682 1183 1.7 <0.01 226 304 1.3 NS 184 256 1.4 NS 
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Thoracic PVAT and inter-scapular BAT are relatively resistant to 
macrophage infiltration under HFD conditions.   
     In order to directly test the extent of macrophage infiltration into BAT and 
PVAT, we immunostained sections of SAT, VAT, BAT and PVAT from the 
thoracic aorta for the macrophage marker F480 (Fig 2.6).  Feeding mice a HFD 
for 13 weeks resulted in significant macrophage infiltration in VAT and SAT, as 
expected (Fig 2.6B,D). In contrast, little or no F4/80 staining was detected in BAT 
or PVAT from these same mice (Fig 2.6F,H).  In order to test whether a longer 
duration of HFD would result in inflammation of BAT or PVAT, we continued HFD 
for 20 weeks in a second cohort of animals (Fig 2.7).  Again, visceral fat showed 
abundant macrophage infiltration (Fig 2.7D), but despite marked enlargement 
and coalescence of lipid droplets in BAT and PVAT, macrophages were absent 
(Fig 2.7F,H).  The same results were obtained after staining BAT and VAT from 
animals fed a HFD for 20 weeks with a second macrophage marker, CD68 (Data 
not shown). 
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FIGURE 2.6. Perivascular and brown adipose tissue are resistant to 
inflammation after 13 weeks high fat diet .  SAT, VAT, BAT, and PVAT from 
the aortic arch was harvested from lean and obese mice (n=3 per group).  
Samples were fixed in 4% formalin, sectioned, and stained with a rat anti-mouse 
F4/80 primary antibody (ABd Serotec).  Staining was visualized with a HRP 
linked rabbit anti-rat secondary anti-body.    Abundant macrophages were seen 
predominantly in VAT, but also SAT, forming crown like structures (arrowheads).  
No macrophages were seen in brown or perivascular adipose tissue. 
(Magnification 25x) 
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FIGURE 2.7. Perivascular and brown adipose tissue are resistant to 
inflammation after 20 weeks high fat diet .  SAT, VAT, BAT, and PVAT from 
the aortic arch was harvested from lean and obese mice (n=3 per group).  
Samples  were fixed in 4% formalin, sectioned, and stained with a rat anti-mouse 
F4/80 primary antibody (ABd Serotec).  Staining was visualized with a HRP 
linked rabbit anti-rat secondary anti-body.    Abundant macrophages were seen 
predominantly in VAT, but also SAT, forming crown like structures (arrowheads).   
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FACS analysis confirms prolonged HFD in mice results in little macrophage 
infiltration of BAT compared to VAT. 
     In order to better characterize the levels of macrophage accumulation in VAT 
versus BAT, we performed FACS analysis on the stromal vascular fraction (SVF) 
of collagenase digested adipose tissue from VAT and BAT in ND and HFD 
conditions.  CD68 and F4/80 markers define total macrophage populations in 
adipose tissue, but do not differentiate between cells at various levels of 
activation [22, 29, 98].   Therefore, after exclusion of CD31+ endothelial cells 
from the SVF, we chose to doubly stain cells for CD11b and CD11c, the latter 
being a marker of classical (M1) macrophage differentiation [98].  Eleven weeks 
of HFD resulted in a striking and significant enrichment of CD11b+/CD11c+ 
macrophages in VAT compared to that observed for BAT (31.7% vs. 1.03%)(Fig 
2.8A).  As we failed to observe macrophage recruitment into BAT with 11 weeks 
of HFD, we extended the duration of the HFD to 20 weeks (Fig 2.8B).  This 
prolonged HFD duration resulted in a marked, significant increase in 
CD11b+/CD11c+ macrophages in VAT, while BAT showed no enrichment of this 
cell population.  Unfortunately, we were unable to perform FACS on PVAT due to 
the small quantity of this tissue in the aortic arch.  However, the results of FACS 
analysis confirm that VAT is enriched with M1 macrophages after 11 and 20 
weeks of HFD, while BAT was resistant to this effect. 
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FIGURE 2.8. Brown adipose tissue is resistant to inflammation after 11 and 
20 weeks of HFD.  (Top) After 11 weeks HFD, the SVF was isolated from VAT 
and BAT and stained with CD31-PE, CD11b-PerCp Cy5.5, and CD11c-PE Cy7.  
Samples were analyzed on a LSRII flow cytometer, gating for CD31 negative 
cells.  High fat feeding resulted in a significant increase in the percentage of 
CD11b and CD11c positive cells in the SVF of visceral but not brown adipose 
(31.7% vs. 1.03%).  (Bottom) Similar results were obtained after 20 weeks of 
HFD.  Results are representative of three independent experiments. 
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Discussion 
     A major finding of the present studies is that PVAT from the murine thoracic 
aorta displays a gene expression pattern that is nearly identical to inter-scapular 
BAT (Fig 2.5, Table 2.1, Supplementary Tables S3 & S4).  The similarity of gene 
expression between PVAT and BAT includes identical expression levels of the 
brown adipocyte genes Cidea, Ucp-1, Dio2, and Prdm16.  Only 0.79% of genes 
represented on chip were differentially regulated between PVAT and BAT in 
normal diet conditions at the stringency level used.  Interestingly, immunoglobulin 
genes were expressed to a greater extent in PVAT; this has also been 
demonstrated in human coronary PVAT [60].  We hypothesize that this due to the 
presence of vascular associated lymphoid tissue [99], although we have been 
unable to visualize such tissue using B cell specific markers (Data not shown).   
     In contrast to these subtle differences between PVAT and BAT, major 
differences between PVAT and WAT were observed in the expression of genes 
previously shown to be highly and selectively expressed in brown or white 
adipose tissues (Table 2.1). Our data thus clarify and definitively substantiate 
previous indications that mouse thoracic PVAT is similar to BAT [74, 91, 100].  
Importantly, these previous studies demonstrate that PVAT can have 
characteristics of both BAT and WAT, but this dichotomy largely depends upon 
the anatomical context; that surrounding the abdominal aorta resembling WAT 
and that surrounding the thoracic aorta BAT [74, 91].  Our studies directly 
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comparing thoracic PVAT gene expression (Table 2.1, Supplementary Tables 
S1-S4, and Fig 2.5) and histological appearance (Fig 2.3) to mouse inter-
scapular BAT show unequivocally that these two adipose depots are virtually 
identical.  This appears different from human coronary PVAT which 
demonstrates an intermediate phenotype between white and brown adipose [89].   
     After 13 weeks of high fat feeding, VAT displayed the expected dramatic 
increase in expression of many immune cell enriched genes, while thoracic 
PVAT and BAT did not. This was somewhat surprising because some previous 
reports indicated that increased infiltration of macrophages and T cells into both 
PVAT [54, 74, 76] and BAT [101, 102] could be detected in mouse models.  Xu et 
al. reported that genetic and diet induced obesity resulted in chronic inflammation 
in WAT but not BAT[29]. Thus the extent of BAT inflammation may greatly 
depend upon the mouse strain and conditions used. Our data are consistent with 
the results of Xu et al. suggesting BAT is comparatively resistant to inflammation 
in C57BL6/J mice after HFD feeding.   
     In contrast to our present findings of very low inflammation of PVAT in mice 
after 13 weeks of HFD, some investigators have proposed that PVAT is an 
intrinsically pro-inflammatory depot [60, 61, 89].  For example, humans with 
established coronary artery disease have higher mRNA and protein levels of IL-
1β, IL-6, MCP-1, and TNFα in epicardial adipose than in paired SAT samples.  
More recently, Chatterjee et al. published data regarding human coronary PVAT 
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and murine thoracic PVAT, the same  anatomic fat depot we have studied here.  
In control mice, relative mRNA expression of Acrp30, Pparγ and Fabp4 was 
lower in PVAT than SAT.  With two weeks of HFD feeding, expression of these 
adipocyte specific genes further declined, while expression of the pro-
inflammatory genes Lep and Mip1α increased [89]. The authors concluded that in 
comparison to SAT, PVAT was poorly differentiated and intrinsically pro-
inflammatory, and hence possibly an etiologic factor in the development of 
vascular disease [89].   
     Our findings are in contrast to the above [89] in that expression of Acrp30 and 
Pparγ2 was not different in thoracic PVAT compared to other fat depots.  A 
possible explanation for the difference in expression of Acrp30 and Pparγ2 
between the two studies is that there may be diet or age dependent changes in 
the expression of these two genes; Chatterjee et al. used a shorter duration HFD 
and younger mice [89].  For example, it may be that younger and older mice than 
those studied herein (21 weeks) are prone to inflammation of PVAT.  Two studies 
which have reported obesity associated inflammation of abdominal and femoral 
PVAT, used 40 week and 22 week old mice respectively[74, 76].  Therefore it is 
likely that many factors including age, strain, diet, and specific anatomic location 
influence whether or not PVAT becomes inflamed.  Finally, although they did not 
report expression of BAT genes in their mouse model, their failure to observe 
significant expression of immune cell specific genes Cd68 and Cd3 by qPCR 
does concur with our results [89].   
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     Importantly, both we and Chatterjee et al. have studied PVAT from the 
thoracic aortic arch, as this a segment of the aorta prone to atherosclerosis both 
in humans and mice [89].  Although PVAT was originally hypothesized to signal 
in a “vasocrine” fashion to influence vascular tone [59], it has subsequently been 
implicated in adventitial inflammation which might promote atherosclerosis [54, 
59-61, 89]; our study was designed to test these latter hypotheses. 
     The overall evidence from the literature combined with our present work 
suggests that PVAT can have different characteristics depending upon its 
anatomical location. Thus BAT-like adipose surrounds the thoracic aorta and 
WAT surrounds the abdominal aorta [74, 91].  As such, we suggest that PVAT 
surrounding the abdominal aorta, like its visceral fat counterpart, is prone to the 
dysregulated adipocyte biology of obesity and subsequent inflammation.  This 
idea has been verified by Takaoka et al., who demonstrated that PVAT 
surrounding the femoral artery is WAT that has beneficial properties in lean 
conditions which are mediated by the paracrine effects of adiponectin 
(Acrp30)[76].  In obese states, inflammation and macrophage infiltration of PVAT 
surrounding the femoral artery results in decreased adiponectin secretion and 
increased Tnfα expression, both of which facilitate pathological neointimal 
hyperplasia in response to vessel injury [76].  In humans, neointimal hyperplasia 
contributes to the pathophysiology of coronary artery disease.  For example, 
diabetes and obesity are associated with increased rates of in-stent restenosis 
following percutaneous intervention (PCI) due to neointimal hyperplasia [77].    A  
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scenario in which white PVAT is beneficial in lean conditions, but becomes 
dysfunctional in obese conditions, is analogous to the current model of obesity 
induced insulin resistance [13]. These and other reports support the concept that 
PVAT with white adipose features conforms to this model [65, 74, 76, 103].  The 
important contribution of our work is that brown PVAT surrounding the thoracic 
aorta appears to be resistant to obesity induced inflammation, and hence may 
offer protection from the associated changes to the arterial adventitia.   
      The finding that PVAT and BAT display little or macrophage infiltration under 
HFD conditions, while WAT does, raises the interesting question: what is unique 
to WAT that causes infiltration of macrophages?  A recent paper by Kosteli et. al 
may shed insight into this important question [34].  Using caloric restriction of 
previously HFD fed mice, the authors showed that rates of adipocyte lipolysis 
correlate with macrophage infiltration.  These studies suggest that the chronic 
elevation in WAT lipolysis observed in obesity causes increased release of fatty 
acids, which serve to stimulate macrophage infiltration [34].  This hypothesis 
offers a potential explanation for why BAT and BAT-like PVAT fail to attract 
immune cells. The unique function of BAT and PVAT to rapidly metabolize fatty 
acids via high capacity for  beta-oxidation likely results in relatively low rates of 
local free fatty acid release from the cells in comparison to WAT [104].  A second 
possibility, is that the fatty acid species released by BAT and PVAT may also 
afford an anti-inflammatory effect. The ratio of saturated to polyunsaturated fatty 
acids has been shown to increase in the VAT and abdominal PVAT of high 
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fructose fed rats [105]. Thus under these conditions WAT may release relatively 
higher levels of saturated fatty acids, which may be more active in stimulating 
macrophage chemotaxis [36, 106].  Finally, abdominal or white PVAT may 
secrete pro-inflammatory adipokines or cytokines.  We have found that although 
white adipose (SAT, VAT) has greater expression of adiponectin, which has anti-
inflammatory effects, it also has greater mRNA expression of adipokines which 
correlate with vascular disease (Rbp4, Resistin)(Table 2.1)[107, 108].  
Furthermore, abdominal PVAT has been shown to secrete greater amounts of 
the chemokine MCP-1 than thoracic PVAT; our data also confirm that Mcp-1(Ccl-
2) mRNA is increased in VAT but not thoracic PVAT after high fat feeding (Table 
2.2)[74].  The comparatively greater diameter of white adipocytes in VAT and 
abdominal PVAT may be one factor responsible for increased Mcp-1 
transcription [109, 110].  
     In summary, results from this present study demonstrate that PVAT 
surrounding the thoracic aorta is effectively BAT, as shown by light and electron 
microscopy, and full genome expression analysis. Thoracic PVAT and inter-
scapular BAT are resistant to inflammation induced by 13 and 20 weeks of HFD, 
as shown by reduced expression of immune cell enriched genes, 
immunohistochemistry with macrophage markers, and FACS analysis for 
activated macrophages.  This work provides an important mandate to study 
expression of BAT genes in human PVAT from patients with and without vascular 
disease.  In light of the recent discovery of functional BAT in adult humans, and 
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given the known beneficial metabolic and herein described anti-inflammatory 
properties of BAT, promotion of a BAT phenotype in the perivascular niche may 
have important effects in preventing vascular diseases such as hypertension and 
atherosclerosis. 
Limitations  
     We acknowledge that there are many limitations to our study.  First and 
foremost, it is merely associative and does not provide any information regarding 
causality, and even if we did observe macrophage infiltration, the HFD fed mouse 
does not develop atherosclerosis or vascular disease.  We are limited in studying 
the effect of perivascular fat in that there are no mouse models of “depot” specific 
fat ablation.  Creation of such technology would greatly advance the field.  It is 
interesting that the lipodystrophic A-FIP/F-1 mouse is hypertensive [111].  
However, these mice have specific white adipose tissue ablation and the 
remaining brown adipose is functionally converted to white. 
     Second, immunohistochemistry of PVAT is not a very sensitive or specific 
technique to exclude the presence of macrophages.  We could not do FACS with 
PVAT due to the limited amount of tissue (10-100 mg).  In the future, we may 
consider verifying our results with rat PVAT, which would provide enough tissue 
to do FACS.   
     Finally, one must question the relevance of the study of brown adipose tissue 
to human physiology.  However, the observation that human epicardial fat 
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expresses intermediate levels of BAT specific genes (PRDM16, UCP-1, CPT1B), 
is what motivated our interest in the first place [89, 112].  Furthermore, the recent 
reports of functional brown adipose tissue in adult humans has reinvigorated the 
field and provided some legitimate rationale for our studies [113, 114]. 
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CHAPTER III:  Protection against diet induced obesity and insulin 
resistance in the apoE knockout mouse is accompanied by an attenuated 
transcriptional response in visceral fat. 
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 Abstract  
       Despite severe hyperlipidemia leading to the development of 
atherosclerosis, apolipoprotein E knockout (EKO) mice are protected from diet 
induced obesity and insulin resistance.  This is counterintuitive to the prevailing 
hypothesis that increased circulating free fatty acids (FFA) and triglyceride rich 
lipoproteins (TGRL) cause peripheral insulin resistance, and may be due to 
defective lipid uptake in target organs of EKO mice.  We tested the hypothesis 
that in this model of atherosclerosis, inflammation of PVAT occurs.  EKO mice 
fed HFD for 24 weeks were leaner and more insulin sensitive than WT 
littermates.  HFD EKO mice had increased post-prandial VO2 and serum β-
hydroxybutyrate.  We were surprised to find that macrophage specific gene 
expression, as determined by either microarray analysis or RT-PCR was not 
increased in either the PVAT or the VAT of HFD fed EKO mice.  While the VAT 
of WT mice had extensive alterations in gene expression in response to HFD, in 
particular, enrichment of inflammatory gene expression and broad down 
regulation of PPARγ target and adipogenic genes, EKO VAT did not.  
Importantly, the EKO VAT instead showed increased expression of genes 
encoding enzymes in fatty acid oxidation pathways.  HFD fed EKO VAT was also 
characterized by smaller adipocyte size and, in comparison to WT HFD, 
decreased staining for the macrophage marker F480+.  We conclude that, 1) 
Inflammation in thoracic PVAT does not occur in conjunction with atherosclerosis 
in EKO mice, 2) EKO mice have increased post–prandial VO2 (ml/hr) and 
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hepatic lipid oxidation, both of which may contribute to their lean phenotype, and 
3) EKO mice remain lean on a HFD despite hyperlipidemia.  The decreased 
adiposity of EKO mice correlates with reduced adipocyte size, reduced adipose 
tissue inflammation and increased expression of genes encoding enzymes 
responsible for oxidation of fatty acids. Consistent with previous work showing 
apoE controls adipocyte uptake and deposition of TG, its absence prevents 
adipocyte hypertrophy and resultant inflammation of VAT. Thus, limiting 
adipocyte acquisition of fatty acids may be advantageous, provided that 
compensatory mechanisms to prevent sustained hyperlipidemia and peripheral 
organ lipotoxicity can be activated. 
Introduction 
     Apolipoprotein E (apoE) is a 34 kD glycoprotein which is a component of all 
lipoprotein particles except low density lipoprotein (LDL)[115].  It is a ligand for 
the clearance of chylomicrons and intermediate density lipoprotein particles (IDL) 
from the circulation via the low density lipoprotein receptor (LDLR), very low 
density lipoprotein receptor (VLDLR) and low density lipoprotein related protein 
1(LRP1)[116].  EKO mice have dramatic elevations of plasma cholesterol (5 fold 
normal) and reduced high density lipoprotein (HDL) concentrations [44, 45].  
These findings mimic those of human patients with Type III hyperlipoproteinemia, 
which results in increased plasma triglyceride (TG) and cholesterol and 
premature atherosclerosis.   
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     Apoe is highly expressed in the liver, adipose tissue, macrophages, and other 
tissues of humans and mice.  In adipocytes, apoE expression is increased by 
PPARγ agonists and decreased by TNF-α [117].  Multiple recent studies have 
documented protection of the EKO mouse from diet induced obesity (DIO) and 
insulin resistance [118-121].  Whole body deficiency of apoE also prevents 
weight gain and insulin resistance in genetic models of obesity such as the ob/ob 
or Ay/+ mouse [119, 121, 122].  Protection from diet induced obesity can be 
reversed by adenoviral over expression of apoE in the liver, suggesting an 
important role for circulating apoE in adipose tissue lipid uptake [119].   
      On the other hand, endogenous adipocyte apoE expression is required for 
the uptake and storage of TG.  For example, primary adipocytes from EKO mice 
cultured in vitro synthesize less TG than WT when incubated with VLDL [123].  
Furthermore, EKO adipocytes transplanted into WT mice fail to increase in size 
in response to 10 weeks of HFD [123].  There are at least two mechanisms by 
which the absence of apoE impairs TG uptake in adipocytes [116, 124].  Binding 
and whole particle uptake of VLDL to EKO adipocytes is impaired due to reduced 
expression and/or decreased cell surface localization of VLDLR, LDLR, and 
LRP1[124].  Lipoprotein lipase (LPL) dependent TG synthesis is also decreased 
in EKO adipocytes.  This is thought to be due impaired fatty acid translocation 
across lipid rafts, as caveolin 1 expression is markedly reduced in EKO 
adipocytes [124].  These same mechanisms may also account for reduced lipid 
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uptake in liver and skeletal muscle, protection from lipotoxicity, and preservation 
of whole body insulin sensitivity despite severe hyperlipidemia [116, 125]. 
     Although EKO mice are protected from the metabolic effects of 
hyperlipidemia, they develop severe atherosclerosis on a normal chow diet at 8-
12 weeks of age [44, 45].  Hyperlipidemia results in the subendothelial retention 
of apoB containing lipoproteins [35].  Monocytes then enter intimal space and 
differentiate into macrophages which engulf modified lipoprotein particles and 
become foam cells [35].  In contrast to adipocytes, uptake of lipid by 
macrophages is not dependent on apoE.  Foam cells take up modified 
lipoproteins via scavenger receptors, predominantly SRA and CD36 [126].  
Rather, apoE in macrophages is important in reverse cholesterol transport and 
lipidation of ApoA1 and HDL by cholesterol export via ABCA1 and ABCG1[127].  
The importance of this function is highlighted by two studies in which bone 
marrow transplantation of apoE+/+ macrophages into EKO mice ameliorates 
atherosclerosis; this is accompanied by improvements in serum lipoprotein 
profiles to wild type levels [128, 129].  Therefore, in contrast to adipocytes and 
other tissues, macrophage specific apoE appears to serve a protective effect in 
respect to lipid handling [127].  This serves to distinguish the role of the 
macrophage in atherosclerosis from its role in diet induced obesity, the depletion 
of which, improves metabolic disease[98].   
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     The specific lipid moieties that stimulate foam cell formation in each case 
might account for these differences.  While it is well established that modified 
lipoprotein particles are the stimulus for foam cell formation in atherosclerosis, it 
has only recently been shown that local FFAs may be responsible for foam cell 
formation in the context of increased lipolysis, such as obesity or fasting [34].    In 
this regard, adipocytes from EKO mice have been shown to have increased rates 
of lipolysis in vitro, therefore we would expect greater inflammation in the VAT of 
these mice [117].   
     Therefore, the aims of this study were to determine 1) is atherosclerosis 
associated with inflammation in thoracic PVAT, 2) is decreased lipid uptake by 
VAT associated with increased expression of genes encoding enzymes 
responsible for de novo lipogenesis and 3) is the visceral adipose tissue of EKO 
mice characterized by increased foam cell accumulation analogous to the 
atherosclerotic plaque? 
Experimental procedures 
Animal Studies- An original colony Apoe-/- (Apoetm1Un) on the C57BL6/J 
background was purchased from the Jackson Laboratory (Bar Harbor, ME).  
Mice were backcrossed to C57BL6/J to obtain WT control littermates.  All 
animals were fed normal chow until 8 weeks of age.  Male wild type and EKO 
mice were then divided into two groups (n=5-6 per group); one fed normal diet 
(ND) and one fed high fat diet (HFD)(42% Milk fat, 0.2% cholesterol, Harlan 
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TD88137) for 24 or 38 weeks respectively.  Animals were fed ad libitum with free 
access to water and housed in the University of Massachusetts (UMASS) 
Medical School Animal Facility with a 12:12 hour light-dark cycle.  Animals were 
weighed weekly for the duration of the diet study.  Intraperitoneal glucose 
tolerance testing was performed as previously described [92].  Area under the 
curve for the GTT was calculated using the trapezoidal method .  At the 
completion of HFD, mice were fasted for 4 hours and then euthanized with CO2 
inhalation and bilateral pneumothorax.  SAT (inguinal), VAT (epididymal), and 
BAT (interscapular) were harvested and snap frozen in liquid nitrogen.  All 
experiments were performed in accordance with protocols approved by the 
Animal Care and Use Committee at UMASS Medical School. 
Metabolic Phenotyping- Body composition was determined non-invasively in 
awake mice using 1H-MRS (Echo Medical System).  For metabolic studies, mice 
were housed under controlled temperature and lighting with free access to food 
and water. The food/water intake, energy expenditure, respiratory exchange 
ratio, and physical activity were performed on three consecutive days using 
metabolic cages (TSE Systems).  Post prandial oxygen consumption was 
calculated by subtracting the pre-fed VO2 (ml/hr)(16:00) from the post-fed 
(VO2)(6:00) as previously described[130]. 
Free Fatty Acid and β hydroxybutyrate Levels- Blood was collected via cardiac 
puncture at the time of euthanasia into heparin coated micro centrifuge tubes and 
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centrifuged at 3000 x g for 15 minutes.  Serum was then decanted and stored at -
80 °C.  Serum free fatty acids were measured with the NEFA (2) colorimetric kit 
according the manufacturer’s instructions (Wako Diagnostics, Richmond, VA).  β 
hydroxybutyrate was measured with a colorimetric assay (#700190) according to 
the manufacturer’s instructions (Cayman Chemicals, Ann Arbor, MI).   
Quantitative PCR- Adipose tissue was isolated as previously described, snap 
frozen in liquid nitrogen and stored at -80°C.  Tissues were homogenized and 
total RNA was isolated with RNA Mini Lipid kits (Qiagen, Valencia, CA).  250 ng 
total RNA was reverse transcribed with the Bio-Rad iScript cDNA Synthesis Kit 
(Bio-Rad, Hercules, CA).  cDNA was diluted 1:5 and 2.5 μl was used in a 12.5 μl 
reaction volume; each reaction was performed in duplicate.  Real time qPCR was 
performed with a Bio-Rad C1000 Thermal Cycler and SYBR Green Master Mix 
(Bio-Rad, Hercules, CA) using the following cycle parameters: 95.0° C for 3 min, 
95.0° for 0:10 min, 60.0° C for 0:15 min, 72.0° C for 0:30 min for 40 cycles.  
Expression was normalized to the reference gene 36b4 using the 2 –ΔΔct method 
[93].  Melt curve analysis was performed to determine the specificity of the PCR 
reaction products.   
Microarray Analysis- RNA was isolated from epididymal VAT as previously 
described.  RNA concentrations were determined using a Nanodrop 2000 
Spectrophotometer (Thermo Fisher, Willmington, DE).  The RNA quality was 
assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA).  Only samples with a RNA Integrity Number >7.5 and normal 18 and 28s 
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fractions on microfluidic electrophoresis were used.  250 ng total RNA was used 
as template for cDNA synthesis and in vitro transcription using the Ambion WT 
Expression kit (Ambion, Carlsbad, CA).  Second strand cDNA was then labeled 
with the Affymetrix WT Terminal Labeling kit and samples were hybridized to 
Affymetrix Mouse Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA).  Gene chip 
expression array analysis for individual genes was performed as previously 
described [94], filtering for p <0.05 and a fold change of >2.  Four biological 
replicate hybridizations per genotype and diet were performed, for a total of 24 
hybridizations.      Robust multi-array average (RMA) was adopted in the UMASS 
Microarray Computational Environment (MACE) to preprocess raw 
oligonucleotide microarray data. The algorithm was implemented as a function of 
the R package Affy [95], which is part of the Bioconductor project [96] using the 
statistical computing language R (R Foundation for Statistical Computing, 
Vienna, Austria).  All statistical calculations are performed using the R statistical 
computing environment and results are stored in a relational database.  The 
preprocessed data are stored as base 2 log transformed real signal numbers and 
are used for fold-change calculations and statistical tests and to determine 
summary statistics. Mean signal values and standard deviations are computed 
for each gene across triplicate experiments and stored in the database. The fold 
change of expression of a gene in two experiments is the ratio of mean signal 
values from these experiments and is always a number greater than one. If the 
ratio is less than one, the negative value of the inverse ratio is stored as fold 
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change. All down regulated genes therefore have a negative fold change value, 
up regulated genes have a positive fold change. In both cases this value is 
greater or equal than one. 
     To determine differential expression of genes in two hybridization experiments 
MACE internally conducts a Student’s t-test with the expression signal values of 
the two hybridizations for all genes in the set. The t-test value and test p-value 
are stored in MACE and can be queried through the MACE user interface. The p-
values stored and displayed as a result of a query are not adjusted for multiple 
testing.   
Histology and Immunohistochemistry- Adipose tissue samples (n=3 per group) 
from normal and high fat diet animals were fixed in 4% formalin for 
immunohistochemistry.  Briefly, samples were embedded in paraffin, sectioned, 
and stained with a rat anti-mouse F4/80 (ABd Serotec, Raleigh, NC)(1:40 
dilution).  Staining was visualized with a HRP linked rabbit anti-rat secondary 
anti-body.  Staining with the secondary antibody alone was performed as a 
negative control.  Images were taken with a Zeiss Microscope and PixeLINK SE 
Software. 
Statistical Analysis- All values are shown as mean ± SEM.  For experiments 
other than the microarray analyses, the Student’s t test for two tailed distributions 
with equal variances was used for comparison between 2 groups; for 
comparisons greater of ≥ 3 groups, two way ANOVA followed by the Bonferroni 
correction was used.   Differences less than p < 0.05 were considered significant.  
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Data was entered into Microsoft Excel and statistical analyses were performed 
with Graph Pad Prism 5. 
Results 
Atherosclerosis is not associated with increased expression of F480, CD68, 
or Mcp-1 in thoracic PVAT 
     In order to test the hypothesis that atherosclerosis is associated with 
increased inflammation in PVAT, we dissected PVAT from the lesser curvature of 
the aortic arch in WT ND, WT HFD, EKO ND and EKO HFD mice (n=6 per 
group).  We also isolated VAT and inter-scapular BAT and SAT as positive and 
negative controls respectively.  qPCR for the macrophage markers F480, Cd68, 
and the chemokine Mcp-1 are shown in Figure 3.1.  Expression was normalized 
to SAT ND for each gene.  Expression of F480 and Cd68 was significantly 
increased in the VAT of WT HFD mice compared to SAT ND (p<0.05).  Although 
Mcp-1 expression was also increased in HFD VAT, it did not reach statistical 
significance.  Expression of F480, Cd68, and Mcp-1 was not significantly 
increased in the PVAT of ND or HFD EKO mice compared to ND SAT.  
Interestingly, expression of these genes was also not increased in the VAT of the 
HFD EKO mouse.  Therefore we concluded that atherosclerosis is not associated 
with increased expression of F480, Cd68, or Mcp-1 in thoracic PVAT.   
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FIGURE 3.1.  Expression of macrophage markers F480 and Cd68 is 
increased in the VAT of HFD mice but not the PVAT or VAT of EKO mice.  
WT and EKO mice were fed ND or HFD for 24 weeks.  RNA was harvested from 
SAT, VAT, BAT and PVAT from the aortic arch.  qPCR was performed and 
expression was normalized to ND SAT using the 2 –ΔΔct method with 36B4 as the 
reference gene.  *p<0.05 vs. WT ND SAT, ***p<0.001 vs. WT ND SAT using the 
Students t test 
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EKO mice are resistant to DIO after 24 and 38 weeks of HFD 
     Male WT and EKO mice were started on ND or HFD at 8 weeks of age (n=5-6 
per group).  After 24 weeks, WT HFD mice were significantly more obese than 
their ND littermates (48.0 ± 1.6 vs. 33.0 ± 0.8 gms, p<0.001)(Figure 3.2A).  In 
contrast, there was no difference between ND and HFD fed EKO mice (34.9 ± 
0.5 vs. 34.8 ± 1.1 gms, p=NS).  Fasting plasma glucose was significantly lower in 
HFD EKO than HFD WT controls and FFA were significantly higher (Table 3.1).  
Intra-peritoneal GTT revealed that HFD WT mice had impaired glucose tolerance 
compared to their ND controls at all time points (p<0.05)(Figure 3.2C).  In 
contrast, there was no significant difference in glucose tolerance between ND 
and HFD fed EKO mice.   
     In a second cohort of animals, we decided to extend the duration of HFD to 
determine if age related impairments in insulin sensitivity might influence fat 
accumulation in EKO mice.  Surprisingly, even after 38 weeks of HFD, there was 
no difference in weight between ND and HFD fed EKO mice (32.4 ± 0.44 vs. 
30.20 ± 0.54, p=NS), nor were there differences in glucose tolerance as seen by 
IP GTT (Figure 3.2D, F). 
     Body composition analyses of mice at 24 weeks of HFD revealed a fivefold 
increase in fat mass of WT mice, whereas HFD EKO mice had a non significant 
doubling of fat mass (Table 3.1).  Diet and genotype had no influence on lean 
body mass (Table 3.1).   
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     In summary, 24 and 38 weeks of a diet high in saturated fat and cholesterol 
results in obesity and diabetes in WT but not EKO mice.  Increased body mass is 
due to a five-fold increase in fat mass of HFD fed WT mice.  This is consistent 
with prior studies and extends these data to high fat feeding of chronic duration.   
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FIGURE 3.2.  EKO mice are resistant to diet induced obesity and impaired 
glucose tolerance after 24 and 38 weeks of HFD.  A,B) Weight of WT and 
EKO mice after 24 and 38 weeks of HFD (n=5-6 per group).  C,D)  Intraperitoneal 
GTT in WT and EKO mice after 24 and 38 weeks of HFD.  E,F)  Area under the 
curve for the IP GTT at 24 and 38 weeks.  *p< 0.05 vs. WT ND, ***p<0.001 vs. 
WT ND using the Student’s t-test 
B) 
 
A) 
 
D) 
 
C) 
 
F) 
 
E) 
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Table 3.1 Metabolic parameters of WT and EKO mice fed ND and HFD for 24 weeks.
 WT ND (n=5) WT HFD (n=5) EKO ND (n=5) EKO HFD (n=6) 
Weight (gms) 31.4 ± 0.7 41.9 ± 0.3*** 32.0 ± 1.0 35.0 ± 2.3 
Fat mass (gms) 3.6 ± 1.0 15.3 ± 0.2*** 3.1 ± 0.7 7.0 ± 1.9 
Lean mass (gms) 26.9 ± 0.8 25.8 ± 0.3 28.3 ± 0.7 27.3 ± 0.8 
24 Hour VO2 Consumption (ml/hr/kg) 3512 ± 126 3073 ± 24 3671 ± 126 3804 ± 294* 
Light phase VO2 Consumption (ml/hr/kg) 3424 ± 116 2883 ± 57 3470 ± 38 3670 ± 267** 
Dark phase VO2 Consumption (ml/hr/kg) 3801± 142 3263 ± 21 4001 ± 150 4066 ± 333 * 
24 Hour VCO2 Production (ml/hr/kg) 3038 ± 138 2379 ± 49 3112 ± 143 2988 ± 251* 
24 Hour Energy Expenditure Rate (kcal/hr/kg) 17.6 ± 0.65 14.7 ± 0.13 17.9 ± 0.65 18.3 ± 1.43 
Raw 24 Hour VO2 Consumption (ml/hr) 112.8 ± 3.2 128.0 ± 1.05 117.2 ± 3.3 125.8 ± 2.8 
Respiratory Exchange Ratio (RER) 0.8 ± 0.01 0.7 ± 0.01††† 0.8 ± 0.01 0.7 ± 0.01††† 
Food intake (gms/day) 3.6 ± 0.55 2.3 ± 0.33 4.3 ± 0.47 2.7 ± 0.14 
Physical activity (counts/day) 4853 ± 413 4853 ± 456 5886 ± 1219 4717 ± 726 
Free fatty acids (mmol/L) 0.5 ± 0.05 0.8 ± 0.16 2.2 ± 0.35^^^ 3.1 ± 3.1^^^ 
Fasting plasma glucose (mg/dl) 185 ± 13 204 ± 11 146 ± 14 148 ± 13* 
GTT AUC (min*mg/dl) 32367 ± 2724 44748 ± 3384*** 26532 ± 2976 32735 ± 2352 
β hydroxybutyrate (mM) 0.36 ± 0.08 0.83 ± 0.24 3.0 ± 0.24 4.9 ± 0.56† 
***p<0.001 vs. WT ND using the Student’s t-test, 
*p<0.05, **p<0.01 vs. WT HFD using two way ANOVA and the Bonferroni correction 
††† p<0.001 vs. ND within genotype using two way ANOVA and the Bonferroni correction 
^^^p<0.001 vs. WT ND, HFD using two way ANOVA and the Bonferroni correction. 
† p<0.001 vs. EKO ND using two way ANOVA and the Bonferroni correction. 
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Metabolic cage studies reveal no differences in energy expenditure, food 
intake, or physical activity 
     We hypothesized that EKO mice might have increased energy expenditure or 
decreased food intake which would account for failure to increase their fat mass 
with high fat feeding.  Metabolic cage analyses were performed for 3 consecutive 
days after mice had been fed HFD for 23 weeks.  There were no differences in 
food intake or physical activity between genotypes; HFD mice tended to eat less 
than their normal chow controls (Table 3.1).   
EKO mice have increased post-prandial, but not total, VO2 or EE 
     EKO HFD fed mice had significantly greater rates of VO2 (ml/hr/kg) over a 24 
hour period than WT HFD fed mice (3804 ± 294 vs. 3073 ± 24 ml/hr/kg, 
p<0.05)(Table 3.1)(Figure 3.3A).  Increased rates of VO2 in EKO mice were 
present in both the light and dark phases.  However, when non-normalized VO2 
(ml/hr) rates were compared, there was no genotype effect, but there was an 
effect of HFD to increase VO2 (ml/hr)(Figure 3.3B)(Table 3.1).  ANCOVA 
confirmed that there was no statistically significant relationship between 
genotype and VO2 or EE (Table 3.2).  In contrast, HFD increased VO2 (R2 0.58, 
p<0.05) and EE (R2 0.76, p<0.001) in both genotypes (Table 3.2).     
     As it has been shown that EKO mice have a prolonged clearance time of 
dietary TG, we hypothesized that they might have an increased post-prandial 
VO2.  Indeed, the difference between pre-prandial (16:00 hours) and post-
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prandial (6:00 hours) VO2 (ml/hr/kg) was significantly greater in EKO HFD than 
WT mice on both diets (p<0.05)(Figure 3.5A).  This effect remained significant 
when non-normalized VO2 (ml/hr) was used (Figure 3.4B).   
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FIGURE 3.3. High fat feeding increases VO2 irrespective of genotype. (A)  
VO2 (ml/hr/kg) was measured using metabolic cages over three consecutive 
days after 23 weeks of HFD in WT and EKO mice (n=5-6 per group).  EKO HFD 
mice had significantly greater rates of VO2 over 24 hours than WT HFD mice 
(p<0.05, Table 3.1).  (B)  When normalization by weight is removed, there is no 
effect of genotype on total 24 VO2 (ml/hr). 
 
A) 
B) 
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Table 3.2 ANCOVA reveals that VO2 (ml/hr) and EE (kcal/ hr) are associated 
with HFD but not genotype. 
 
 
 
 
 
Model for EE  Source DF F Value P value 
 Genotype 1 1.93 0.186 
 Diet 1 29.08 <0.001* 
 Genotype * Diet 1 5.32 0.036* 
 Weight 1 0.11 0.746 
 Fat Mass 1 0.01 0.942 
 Lean Body Mass     1 0.71     0.413 
     
Model for VO2 Source DF F Value P Value 
 Genotype 1 0.36 0.560 
 Diet 1 8.41 0.011* 
 Genotype * Diet 1 1.87 0.193 
 Weight 1 0.16 0.699 
 Fat Mass 1 0.11 0.749 
 Lean Body Mass 1 0.33 0.572 
*Diet is a significant independent predictor of EE and VO2 using ANCOVA.  
Diet remains significant in the EE model when the interaction term 
Genotype * Diet is removed. 
101 
 
 
 
FIGURE 3.4.  Post-prandial VO2 is increased in HFD EKO mice compared to 
wild type ND and HFD mice.  (A) The difference in VO2 (ml/hr/kg) before and 
after the dark (feeding) cycle.  The difference VO2 was significantly greater in 
EKO HFD than WT ND and WT HFD fed mice.  (B)  The difference in post-
prandial VO2 (ml/hr) remained when normalization by weight was removed. 
*<0.05 vs. WT ND, WT HFD using two way ANOVA and the Bonferonni 
correction. 
 
B) 
A) 
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EKO mice are protected against hepatic steatosis induced by 24 weeks of 
HFD 
     Although it is well known that EKO mice have severe elevations of blood 
cholesterol and TG, given that they have greater rates of VO2 (ml/hr) in the post-
prandial period, we hypothesized that they may be consuming some fraction of 
this excess fatty acid via hepatic β-oxidation.   Light microscopy showed that 
HFD EKO mice were protected from hepatic steatosis, while HFD fed WT mice 
had severe hepatosteatosis with hepatocyte ballooning and large lipid droplet 
formation (Figure 3.5).  In addition, serum β-hydroxybutyrate concentrations were 
5 fold higher in EKO HFD than wild type HFD mice (4.9 ± 0.56 vs. 0.83 ± 0.24 
mM, p<0.001)(Table 3.1).  This supported our hypothesis that decreased fat 
storage in adipose tissue results in increased delivery of fatty acids to the liver, 
which is used as substrate for β-oxidation and ketone formation. 
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FIGURE 3.5.  EKO mice are protected against hepatic steatosis induced by 
24 weeks of HFD.  Hematoxylin & eosin staining of liver sections from WT (top) 
and EKO mice (bottom) after 24 weeks of ND (left) or HFD (right).  WT HFD mice 
have severe hepatocyte ballooning and macrosteatosis.  In contrast, EKO HFD 
mice have much less lipid accumulation and hepatocyte ballooning.  
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Comparative insensitivity of EKO VAT gene expression in response to HFD 
     Given that EKO mice have an impaired ability to uptake and store dietary fat 
as TG, we hypothesized that adipocytes might compensate by stimulating de 
novo lipogenesis.  Increased glucose uptake by adipose tissue would allow for 
this and partially explain the improved glucose tolerance of EKO mice.  
Therefore, we queried expression of key transcription factors (Srebf1, 
Nr1h3/Lxrα) and regulatory enzymes (Acly, Fasn) which regulate de novo 
lipogenesis using qPCR.  We were surprised to find that obese HFD WT mice 
had significantly increased expression of Fasn (3.3 fold), Acly (4.3 fold), Srebf1 
(3.0 fold), and Dgat2 (5.9 fold) while HFD EKO mice had no such increase 
(Figure 3.6).  In comparison to ND controls, HFD fed EKO mice had a decrease 
in expression of all these genes, two of which were statistically significant 
(Lxrα/Nr1h3 0.44 fold, Dgat2 0.33 fold)(Figure 3.6).   
     To gain a more comprehensive picture of these changes in gene expression, 
we performed whole genome expression profiling of VAT from WT and EKO mice 
fed ND and HFD for 24 weeks using the Affymetrix Mouse Gene 1.0 ST chip.  
We defined differential expression as a fold change >1.5 at an α of p<0.05.  
When comparing ND WT to HFD WT adipose tissue, expression of 880 genes 
was significantly different between conditions (3% of represented probes)(Supp. 
Table 3.1).  In contrast to WT VAT, EKO VAT was remarkably insensitive to 
dietary fat in terms of quantitative changes in gene expression.  Expression of  
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FIGURE 3.6. mRNA expression of genes encoding key transcription factors 
and metabolic enzymes which regulate fatty acid metabolism are up 
regulated in WT but not EKO HFD adipose tissue. 
qPCR for select genes was performed on RNA isolated from epididymal VAT of 
normal and HFD fed WT and EKO mice.  Fold expression is in comparison to ND 
controls of the respective genotype.  Dashed line is the mean expression in ND 
controls.  *p<0.05 vs. ND control using Student’s t-test, N=3 per group.  
Acaa2=Acetyl coA acyltransferase 2 , Dgat2=Diacylglycerol O acyltransferase 2, 
Fasn=Fatty acid synthase, Acly=ATP citrate lyase, Pparg=Peroxisome-
proliferator activated receptor gamma, Srebf1=Sterol response element binding 
factor 1, Nr1h3=Nuclear receptor sub family 1, group H, member 3
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only 53 genes were differentially regulated in EKO adipose tissue when 
comparing ND versus HFD (0.1% of represented probes)(Supp. Table 3.2).  
BIOCARTA pathway analysis for this comparison revealed pathways known to 
be regulated in fatty acid metabolism, including ChREBP2, Leptin, and AT1R 
pathways (Table 3.3).  In contrast, he top ten pathways for the WT analysis were 
all inflammatory pathways, including T helper, B lymphocyte, and dendritic cell 
pathways (Table 3.3). 
     We then specifically queried expression of an a priori determined list of genes 
whose products encode proteins which function in fatty acid metabolism, 
including PPARγ target genes, pro-adipogenesis genes, β oxidation genes, and 
cholesterol metabolism genes (Table 3.4).  PPARγ target genes such as insulin 
receptor substrate 1 (Irs1), Complement component d (Cfd), facilitated glucose 
transporter member 4 (Glut4/Slc2a4), and adiponectin (Adipoq) were uniformly 
and significantly down regulated in response to HFD in WT mice (p<0.05)(Table 
3.4).  In contrast, PPARγ target genes were not down-regulated in EKO adipose 
tissue.  Interestingly, genes belonging to cholesterol metabolism pathways were 
significantly up-regulated in the HFD fed WT mice, whereas there was no 
response to HFD in EKO adipose tissue.  The only gene set consistently up-
regulated in HFD fed EKO mice were those encoding enzymes responsible for 
fatty acid catabolism and β oxidation (Table 3.4).   
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Pathway analysis of WT ND vs. HFD VAT 
Index                Gene Set Category                             Set Size       % up           NTK Stat             NTK q 
259 TCRA pathway 10 0 4.97 <0.001 
32 Extrinsic pathway 13 15 3.5 <0.001 
154 B Lymphocyte pathway 9 0 4.8 <0.001 
51 T helper pathway 12 0 4.3 <0.001 
261 DC pathway 20 15 4.4 <0.001 
237 T cytotoxic pathway 12 0 4.0 <0.001 
138 ASB cell pathway 11 9 3.0 0.012 
145 NO2 IL12 pathway 16 18 3.4 <0.001 
254 Lair pathway 15 20 4.0 <0.001 
239 Csk pathway 19 31 2.8 <0.022 
Pathway analysis of EKO ND vs. EKO VAT 
    Index G                  Gene Set Category                   Set Size       % up            NTK Stat           NTK q 
104 Differentiation pathway in PC12 40 75 -5.4 0 
157 Granule cell survival pathway 24 75 -4.0 0 
101 P53 hypoxia pathway 22 90 -4.2 0 
127 Chrebp2 pathway 39 82 -5.1 0 
40 Leptin pathway 11 81 -3.7 0 
53 CTCF pathway 22 86 -4.1 0 
87 VDR pathway 11 90 -3.97 0 
166 CARM ER pathway 34 70 -3.9 0 
38 CD40 pathway map 33 69 -3.8 0 
15 AT1R pathway 29 82 -4.8 0 
 
TABLE 3.3 BIOCARTA Pathway Analysis of Differentially Expressed Genes 
in WT ND vs. HFD and EKO ND vs. HFD 
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TABLE 3.4 Differential regulation of metabolic gene sets in response to 
HFD in WT vs. EKO 
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Reduced cell size and macrophage F480 staining in EKO HFD VAT 
     Considering the dramatic increase in expression of inflammatory genes in the 
WT HFD VAT (Table 3.3)(Supplementary Table 3.1) we decided to confirm the 
extent of macrophage infiltration with HFD by immunohistochemistry for the 
macrophage marker F480+ (Figure 3.7).  WT HFD VAT had abundant 
macrophage F480+ staining, with most appearing as large multi-nucleate cells in 
crown like structures (CLS).  In contrast, there very few macrophages or CLS in 
the EKO HFD VAT.  In addition, the diameters of EKO WT and HFD VAT 
adipocytes were much smaller than WT, which is consistent with previous 
reports. 
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FIGURE 3.7 WT HFD VAT has larger adipocytes and greater F480+ 
Macrophage staining.   
Epididymal VAT from WT and EKO mice fed ND and HFD for 24 weeks was 
harvested and stained with the macrophage specific marker F480+.  WT 
adipocytes were larger than EKO at baseline and with HFD and contained 
greater numbers of F480+ cells. 
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Discussion 
     It is now well established that the EKO mouse is resistant to DIO and remains 
glucose tolerant when compared to WT HFD fed controls [118-120, 122, 131, 
132].  Our results confirm these prior studies and make three novel contributions: 
1) inflammation in PVAT is not associated with atherosclerosis in the EKO 
mouse, 2) post-prandial, but not total, VO2 (ml/hr) is increased in HFD fed EKO 
mice, 3) EKO mice remain lean on HFD, and this is associated with decreased 
adipocyte size, reduced inflammation, and increased expression of fatty acid 
oxidation genes.                  
     The failure to observe increased macrophage gene expression in thoracic 
PVAT of EKO mice does not exclude the possibility that PVAT is important in the 
pathogenesis of atherosclerosis.  There are at least two significant limitations to 
our experiment which prevent us from making this conclusion.  One, by 24 weeks 
of age, atherosclerosis in the EKO mouse is relatively advanced, and may be in a 
chronic, non-inflammatory stage.  In order to determine if inflammation in PVAT 
is an initiating event, we would have to use younger animals prior to the 
development of atherosclerosis (approx 6-8 weeks of age)[133].  Second, 
although we dissected PVAT from an atherosclerosis prone area (the aortic 
arch), we cannot be sure that there was actual plaque in the adjacent vessel in 
every mouse.  Nonetheless, we are confident that inflammation of PVAT is not an 
initiating event in the patho-physiology of atherosclerosis.  Whether or not it has 
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significance in other forms of obesity related vascular disease is a topic of future 
studies (Chapter IV).   
     Regarding our studies of whole body metabolism, compared to WT controls 
EKO mice had a significantly reduced fat mass in response to HFD; this was 
apparent within 8 weeks of starting a HFD, and continued until 24 and 38 weeks 
(Fig 3.2).  WT mice had a 5 fold increase in fat mass after 24 weeks HFD while 
EKO mice had only a 2 fold increase (Table 3.1).  Huang et al. have shown that 
endogenous adipocyte apoE is required for both LPL dependent and VLDR 
endocytic uptake of triglyceride rich lipoprotein particles, and this would account 
for reduced fat mass [124].  However, how do we account for the apparent 
caloric imbalance in EKO mice?   
     We detected no differences in food intake or physical activity between WT 
and EKO animals (Table 3.1).  Others have shown that intestinal absorption of 
lipid is normal in the EKO mouse[134].  Therefore, we hypothesized that EKO 
mice might have increased energy expenditure.  Gao et al. found that EKO mice 
on the Ay/+ background had increased VO2 in light and dark phases [119].  In 
contrast, Hofmann et al. found no differences in energy expenditure after 16 
weeks of HFD [120].  Indeed, we found that when VO2 was normalized to body 
weight (ml/hr/per kg body weight) HFD fed EKO mice had greater rates of VO2 
(Table 3.1, Figure 3.3A).  However, when we analyzed raw or non-normalized 
VO2 (ml/hr), there was no significant difference between groups (Table 3.1, 
Figure 3.3B).  ANCOVA revealed that diet, but not genotype, was significantly 
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associated with VO2 (ml/hr) and EE (kcal/hr).  The linear model incorporated 
weight, lean body mass, and fat mass as covariates to account for these 
independent variables (Table 3.2).  Our use of non-normalized measures of 
energy expenditure and ANCOVA are in conformity with a recent consensus 
statement by an expert panel of scientists [135].  It is likely that all prior studies  
which included body weight in the estimation of VO2 (ml/hr/kg) and EE 
(kcal/hr/kg) erroneously ascribed a greater energy expenditure to EKO mice.  
Despite these issues, we did find that non-normalized post-prandial VO2 (ml/hr) 
was significantly greater in HFD EKO mice than HFD WT mice, a factor which, 
over the life of the animal, may contribute to reduced weight gain (Figure 
3.4)[136]. 
     Consistent with prior reports, we found that the livers of HFD fed EKO mice 
were resistant to hepatosteatosis (Figure 3.5)[118, 119, 132, 134].  As apoE is a 
ligand for the LDL, VLDL, and remnant receptor (LRP1), the liver cannot take up 
chylomicron remnants and LDL and therefore may be less prone to lipotoxicity.  
This highlights the important contribution of dietary fat to hepatic steatosis.  
However, as VLDL secretion is also dependent upon apoE, and rates of hepatic 
VLDL secretion are decreased in EKO mice, one might expect hepatic TG to 
accumulate despite reduced uptake [137, 138].  We observed the exact opposite, 
that EKO mice were protected from hepatosteatosis with HFD.  Increased 
hepatic β-oxidation of fatty acids may reduce liver TG accumulation in EKO mice 
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[134].  The increased plasma β-hydroxybutyrate concentrations that we observed 
in ND and HFD EKO mice are consistent with this idea (Table 3.1). 
     Perhaps the most dramatic findings of our study stem from the microarray 
analyses. (Table 3.4 & Supp. Tables 3.1, 3.2) High fat diet feeding in EKO mice 
resulted in significantly altered expression of only 0.1% of probe sets; in contrast, 
WT HFD mice had a 30 fold greater number of genes whose expression was 
altered in response to HFD (3%).  We initially hypothesized that EKO adipocytes 
may compensate for decreased TG uptake by increasing de novo fatty acid 
synthesis.  qPCR showed that that genes encoding lipogenic enzymes (Acly, 
Fasn, Dgat) were up-regulated in WT HFD adipocytes but not in EKO adipocytes 
(Fig 3.6).  We then queried the microarray data for an a priori determined list of 
genes involved in fatty acid metabolism.  We again failed to detect an increase in 
expression of the same lipogenic genes in EKO adipocytes.  However, we did 
find some interesting patterns of expression which correlated with our metabolic 
studies (Table 3.4).   
     First, important PPARγ target genes such as Adipoq, Cfd, Irs1 and 
Glut4/Slc2a4, were all down regulated in response to HFD in WT VAT; this 
correlated with the potent inflammatory response in this tissue and impaired 
whole body glucose metabolism (Table 3.4).  Inflammation, specifically TNFα, is 
thought to reduce PPARγ activity in adipocytes [13].  Second, a panel of genes 
encoding proteins in the cholesterol biosynthesis pathway (Hmgcs1, Insig1, Lss, 
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Hsd17b7) were up regulated in WT HFD fed VAT (Table 3.4).  It has been shown 
in previous studies that large adipocytes are cholesterol deficient due to their 
requirement for a large plasma membrane, therefore they activate expression of 
genes to increase cellular cholesterol [139].  In that regard, it is also notable that 
the expression of the VLDL (1.4 fold, p<0.05)  and LDL (1.8 fold, p=NS) 
receptors was increased (1.4 fold) in the WT HFD mice, likely as an additional 
mechanism to increase cellular cholesterol (Supp Table 3.1).  Cholesterol 
deficiency causes cellular insulin resistance by reducing signaling through 
caveolin 2 enriched lipid rafts [139].  Of note, the diameter of WT type adipocytes 
was much greater than EKO adipocytes at baseline and especially with HFD (Fig 
3.7)..   
     In regards to the increased numbers of macrophages in the WT HFD VAT, the 
microarray data indicate that multiple mechanisms of macrophage lipid uptake 
appear to be activated, all of which parallel foam cell formation in the 
atherosclerotic plaque.  For example, enzymatically modified LDL particles are 
internalized mainly by type 1 (opsonin) and type 2 (complement) mediated 
phagocytosis [140].  Expression of both Cd16/Fcgr3, which binds C reactive 
protein and IgG coated LDL particles, and Cd11b, which binds complement 
coated LDL particles, is increased in WT HFD VAT (1.48 and 1.71 fold 
respectively p<0.05, Suppl. Table 3.1).  Type 1 and type 2 phagocytosis lead to 
the formation of large, membrane associated lipid droplets [140].  In contrast, 
expression of the macrophage scavenger receptor Msr1, which is responsible for 
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receptor mediated of predominately oxidized LDL particles, is also increased 
(1.92 fold, p<0.05, Suppl. Table 3.1).  Expression of these genes is not altered in 
EKO VAT with HFD.  We do not suggest that modified and oxidized LDL are 
necessarily the ligands for macrophages in adipose tissue, only that it is likely 
that there are multiple complex lipid antigens released from dying (or viable) 
adipocytes in WT HFD VAT which broadly stimulate the innate immune 
response.  The decreased cell size of EKO HFD adipocytes may prevent cellular 
stress and death thus preventing this inflammatory response.   
     That we do not see increased macrophages in the VAT of HFD EKO mice is 
not inconsistent with the results of others who have shown that 1) primary EKO 
adipocytes have increased rates of lipolysis ex vivo and 2) FFA release is a 
stimulus for macrophage infiltration [34, 117].  On cellular basis, because the 
lipolytic rate depends on cell surface area (4πr2), and EKO adipocytes are 
almost ½ the diameter of WT adipocytes, FFA release per cell is actually likely 
much smaller in EKO adipocytes.  Second, rates of lipid oxidation may be 
increased in EKO adipocytes, resulting in less release of FFA from hydrolyzed 
TG.  Finally, macrophage infiltration in response to lipolysis has been shown in 
obese animals subjected to fasting, thus, in negative energy balance, which was 
not the case for EKO mice [34]. 
     In regard to changes in gene expression in EKO adipose tissue, expression of 
genes encoding enzymes important for fatty acid oxidation were broadly up-
regulated, for example, Oxpat/Plin5, Cox8b, Acsl5, Acox1, and Acadl (Table 3.4).  
117 
 
Many of the same genes were down regulated in WT HFD VAT.  Interestingly, 
the gene with the highest fold increase in expression in EKO HFD VAT, lactase-
like (Lctl), is a recently described member of the fibroblast growth factor family 
which is specifically expressed only in brown adipose tissue [141](Supp Table 
3.2).  Whether or not fatty acid oxidation is actually functionally increased in EKO 
adipocytes, and relates to their decreased cell size, will require further study. 
     In summary, using a combination of physiologic studies, genomics, and 
immunohistochemistry, we describe some novel findings regarding the metabolic 
phenotype of EKO mice which will provide a starting point for future studies.  We 
confirmed the observation that, despite severe hyperlipidemia, EKO mice fed a 
HFD are more lean and insulin sensitive than their WT littermates.  This may be 
due to failure of adipose, skeletal muscle, and liver to properly metabolize 
circulating triglyceride rich lipoproteins.  Second, using careful statistical analysis 
of metabolic cage data in accordance with expert guidelines, we show that post-
prandial VO2 (ml/hr), but not total VO2 or EE is increased in EKO mice.  This 
may partially account for their lean phenotype.  Finally, using the first whole 
genome comparison of gene expression of WT and EKO adipose tissue, we 
show that EKO mice have decreased expression of inflammatory genes, and 
increased expression of genes encoding enzymes responsible for lipid oxidation.  
These results suggest that limiting adipocyte size or TG uptake may be a viable 
therapeutic strategy, provided that peripheral mechanisms to prevent atherogenic 
hyperlipidemia can be activated.   
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Limitations 
     We acknowledge the many limitations of this study.  We hypothesized that the 
EKO adipocytes would compensate for reduced lipid uptake by increased de 
novo lipogenesis.  Although we did not see increased expression of genes 
encoding lipogenic enzymes, it is still possible that enzymatic activity is indeed 
high and that increased rates of de novo lipogenesis do exist.  We do plan to 
specifically measure this in the future using in vivo lipogenesis assays with C14 
glucose. 
     The metabolic cage studies should ideally be done at two points in time, one 
preferably before differences in weight exist (8 weeks of HFD in our case), so 
that differences in VO2 and EE can be longitudinally associated with the 
development or prevention of obesity. 
     Post-prandial VO2 was an estimate based on the metabolic cage data.  This 
experiment should be repeated formally with a test meal and measurement of 
metabolic rate for 4 hours after the meal [136]. 
      Microarrays were done on whole adipose tissue, which contains multiple cell 
types, all of which could confound our results.  For example, the increased 
expression of enzymes responsible for cholesterol biosynthesis could be due to 
increased macrophages/foam cells in the WT HFD VAT. 
     These limitations aside, we believe that we have made novel contributions to 
the field of knowledge regarding this fascinating model of lipid metabolism.  We 
conclude that: 1) inflammation in PVAT is not associated with atherosclerosis in 
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the EKO mouse, 2) post-prandial VO2 (ml/hr) is increased 3) HFD fed EKO mice 
are protected from hepatic steatosis possibly due to increased hepatic lipid 
oxidation, 4) EKO mice remain lean on HFD, and 5) this is associated with 
decreased adipocyte size, reduced inflammation, and increased expression of 
fatty acid oxidation genes.                  
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CHAPTER 4: Summary and Future Directions 
     The contributions of obesity and the metabolic syndrome to cardiovascular 
risk are well described [7, 8, 13].  Visceral adiposity, but not subcutaneous, is the 
primary trigger for the development of the metabolic syndrome.  This contrast 
between SAT and VAT has motivated interest in the discovery of additional fat 
depots which might play equally important roles in metabolic disease.  
Perivascular fat is one such depot, and the work described herein was an 
attempt to understand if PVAT plays a direct role in vascular disease.  Although 
we did not demonstrate a primary role for PVAT in atherosclerosis, we did make 
novel observations regarding the characteristics of PVAT in the mouse and how 
it is influenced by high fat feeding.   
     In the first chapter of this thesis we established that thoracic PVAT is similar 
to brown adipose using morphology and whole genome expression analyses.  
We also demonstrated that thoracic PVAT and BAT are comparatively resistant 
to HFD induced inflammation.  This inflammation is characterized predominantly 
by F480/Cd11c+ macrophages.  We hypothesize that the absence of 
inflammation in thoracic PVAT and BAT may be due to decreased cell size, 
decreased chemokine release, or decreased release of FFA.   
     In the second chapter of this thesis, we asked the question “is atherosclerosis 
in the mouse associated with inflammation in PVAT?”.  We did not find evidence 
of increased expression of macrophage specific genes in the PVAT of the 
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thoracic aorta of the EKO mouse by qPCR.  We did observe that the EKO mouse 
was protected from HFD induced obesity and glucose intolerance.  EKO mice 
were less obese and more glucose tolerant than their WT HFD fed littermates.  In 
addition, the VAT of EKO mice was characterized by fewer alterations in gene 
expression in response to HFD.  In particular, very few inflammatory genes 
appeared to be regulated in the EKO mouse; this was associated with reduced 
inflammation in VAT as seen by F480+ macrophage staining.  These 
experiments reinforce the importance of dietary fat in genesis of VAT 
inflammation, and show that apoE is essential for adipose tissue uptake of TG. 
      The above findings have lead to many new questions and directions for 
further research.  What is the reason for the apparent resistance of BAT to diet 
induced inflammation?  Does PVAT actually have a role in vascular disease?  
Most importantly, do these questions have relevance to human disease?  I will 
conclude this thesis with a brief description of two experiments we are 
conducting that will more definitively answer these questions. 
Influence of adipocyte specific Mcp-1 knockout on abdominal aortic 
aneurysm formation in HFD fed mice. 
     Abdominal aortic aneurysm (AAA) in humans is independently associated with 
measures of central obesity such as waist circumference and waist to hip ratio 
[73]. Circulating markers of macrophage function such as resistin and 
osteopontin have also been associated with the presence of AAA [73, 142]. 
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Inflammation of all three layers of the aorta has been noted on pathological 
specimens of AAA; however, it is still unclear where exactly local inflammation is 
incited.  
     In contrast to thoracic PVAT, PVAT surrounding the abdominal aorta is white 
adipose tissue, and like VAT, is prone to obesity induced inflammation 
[74](Figure 4.1).  In response to HFD abdominal PVAT has increased expression 
of Mcp-1 and F4/80(Figure 4.2).  In addition, Police et al. have shown that Mcp-1 
release into conditioned media is greater in abdominal than thoracic PVAT, and  
this is accompanied by a greater ability of conditioned media from abdominal, but 
not thoracic PVAT, to stimulate macrophage migration [74].   
     The significance of these observations is that AAA in obese mice and humans 
is associated with macrophage infiltration of the local PVAT, whereas the 
thoracic aorta is spared from aneurysm formation in obesity [61, 74]    Hence, it 
seems that abdominal PVAT is very much like visceral fat.  However, a major 
question remains is the adipocyte the primary source of Mcp-1 in HFD induced 
obesity?  Therefore, we will test the hypothesis that adipocyte specific knockout 
of Mcp-1 reduces the incidence and size of AAA in HFD fed mice after 
angiotensin II infusion. 
     Mcp1LoxP/LoxP mice on the C57BL/6 background haven been generated by Dr. 
Teizo Yoshimura from the NCI/NIH.  Mice will be crossed with an adipocyte 
specific Cre recombinase driven by the adiponectin promoter(AdipoqCre)[143].  
AdipoqCreMcp1LoxP/LoxP  and Mcp1LoxP/LoxP control mice will be started on a HFD at  
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FIGURE 4.1.  A working model for the contribution of PVAT to abdominal 
aortic aneurysm formation in obesity. 
In mice, the fat surrounding the thoracic aorta is brown adipose, while that 
surrounding the abdominal aorta is predominantly white adipose.  High fat 
feeding of rats has been shown to result in increased growth and weight of the 
abdominal but not the thoracic PVAT.  Furthermore, in humans, obesity is 
independently associated with aneurysms of the abdominal, but not the thoracic 
aorta.  We hypothesize that this is due obesity induced inflammation in the 
abdominal PVAT, with subsequent weakening of the aortic adventitia and 
aneurysm formation. 
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FIGURE 4.2. Increased Mcp-1 and F480 mRNA in abdominal PVAT  
correlates with macrophage infiltration. 
RNA was prepared from thoracic and abdominal PVAT and qPCR was 
performed for Mcp-1 (A) and F480 (B)(n=3 mice per tissue and diet).  F480 
staining in abdominal PVAT of mice fed ND (C) or HFD (D) for 20 weeks.  
Abundant macrophages in CLS were apparent in abdominal PVAT of HFD fed 
mice (arrows). (Tim Fitzgibbons, unpublished data) 
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8 weeks of age (n=10 mice per group).     After 3 months, mice will have blood 
pressure taken via tail cuff and then we will measure baseline diameter of the 
suprarenal abdominal aortic with ultrasound.  Alzet 2004 minipumps will then be 
inserted and Angiotensin II will be infused (1000 ng/kg-1/min-1) for 28 days to 
induce AAA formation[74].  Ultrasound will be repeated at the study end to 
measure abdominal aortic dimension and then mice will be euthanized.  The 
circulation will be perfused with ice cold PBS and SAT, VAT, and abdominal 
PVAT will be collected and snap frozen in liquid nitrogen.  The suprarenal 
abdominal aorta will photographed in situ using a Nikon dissecting scope, and 
maximal diameter of the suprarenal aorta will be measured offline. 
       US measured aortic diameter at baseline and at study end will be compared 
between the  HFD Mcp1LoxP/LoxP  and the HFD AdipoqCreMcp1LoxP/LoxP.  Ex vivo 
measurement of the maximal diameter of the suprarenal abdominal aorta will 
also be compared between groups.   
     I expect that the diameter of the suprarenal abdominal aorta will be 
significantly greater in the HFD Mcp1LoxP/LoxP than in the HFD 
AdipoqCreMcp1LoxP/LoxP and the ND Mcp1LoxP/LoxP group.  This relation will hold 
true for both the US and ex vivo derived measurements.  I expect that incidence 
of AAA formation, defined as a greater than 50% enlargement of the maximal 
aortic diameter as measured by US at baseline in comparison to study end [144], 
will be greater in the HFD Mcp1LoxP/LoxP  than in the HFD AdipoqCreMcp1LoxP/LoxP.   
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     A potential weakness of this study design is that Mcp-1 is not deleted 
specifically in the abdominal PVAT, but rather in whole body adipose tissue.    
Nevertheless, documentation of reduced macrophage infiltration by qPCR and 
immuno-histochemistry, and a reduction in the incidence or size of abdominal 
aortic aneurysm in the HFD AdipoqCreMcp1LoxP/LoxP group would be convincing 
evidence of an adipose specific effect. 
 
Comparison of inflammatory gene expression from epicardial fat in 
patients with and without coronary disease. 
     Multiple studies have demonstrated increase expression of inflammatory 
genes in epicardial fat from humans with advanced coronary disease [60, 62].  
Few of these studies have included control patients without coronary disease.  
Additionally, there are an increasing number of papers which report increased 
cardiovascular risk per unit size of epicardial fat thickness/mass.  However, much 
if not all of this risk disappears when measures of visceral adiposity are 
controlled for (i.e. BMI, waist circumference, or VAT volume by CT/MRI)[69, 70].  
Therefore, it remains to be demonstrated whether or not EAT is an independent 
fat depot with unique features, or merely a marker for increased visceral 
adiposity.   
     In this study we will compare gene expression in epicardial fat from patients 
with and without coronary disease.  Our aim is to answer three specific 
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questions: 1) does the whole genome expression profile of epicardial fat differ 
from that of visceral fat from age and BMI matched controls?, 2) are BAT specific 
genes expressed to a greater degree in those without coronary disease, and 3) 
are inflammatory specific genes expressed to a greater extent in those with 
coronary disease? 
     We will enroll 6 controls (patients have valve surgery who do not have CAD) 
and 6 cases (patients having bypass surgery for CAD)(Figure 4.3).  Fasting blood 
will be drawn on the day of surgery.  Samples of EAT proximal to the right 
coronary artery will be taken, and SAT from the sternotomy incision site.  
Samples will be snap frozen in liquid nitrogen for subsequent RNA analysis.  
RNA will be prepared and hybridized to Affymetrix Human Gene 1.0 ST arrays.  
Data will be uploaded into the UMASS MACE (Microarray Computational 
Environment).   
     To determine if EAT has a different whole genome expression profile than 
VAT, we will compare expression in controls to age and gender matched 
expression data from VAT which we have from a cohort of gastric bypass 
patients previously described[25].  We will then compare expression of BAT and 
immune cell specific genes in cases and controls.  We will correlate expression 
data in cases with the severity of CAD as assessed by scoring angiograms with 
the Gensini scoring system. 
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FIGURE 4.3.  Experimental design of the REACD (Role of Epicardial 
Adipose in Coronary Disease) Study. 
Cases with and controls without CAD will be enrolled in the study.  Fasting blood 
will be drawn on the day of surgery for isolation of plasma and peripheral blood 
monocytes.  Samples of EAT and SAT will be taken at the time of surgery. 
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    I expect that EAT may have a similar expression profile as VAT, with the 
exception of patterning and other developmental genes.  I also expect that BAT 
specific genes may be expressed to a low degree and correlate inversely with 
age, as has been previously shown for Ucp-1 and Prdm16 [112].  Finally, I 
expect that EAT from patients with CAD will have significantly greater enrichment 
of inflammatory gene expression.  The ultimate aim of these studies is to develop 
siRNA therapeutics which can be used topically at the time of cardiac surgery to 
prevent graft restenosis, post-operative atrial fibrillation, or progressive adverse 
cardiac remodeling. 
Conclusion 
     Obesity is independently associated with an increased risk cardiovascular 
disease, much of which is mediated by the metabolic syndrome and underlying 
insulin resistance.  Visceral adiposity in particular has been shown to be 
associated with this risk.  We propose that there may be additional, direct 
mechanisms, by which obesity may impact cardiovascular disease, via 
perivascular and epicardial fat.  In the mouse, we have shown that PVAT around 
the thoracic aorta is BAT.  Whether or not brown perivascular fat exists in 
humans has yet to be determined, but is a very intriguing hypothesis.  Brown fat 
in the perivascular niche could directly warm the blood, serve to take up and 
consume triglyceride rich lipoproteins, and protect the underlying artery from 
inflammation.  We believe that the work described herein and our future aims 
provide an impetus to pursue these important questions.  
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